WO2003097846A1 - Recombinant poxvirus expressing homologous genes inserted into the poxviral genome - Google Patents

Recombinant poxvirus expressing homologous genes inserted into the poxviral genome Download PDF

Info

Publication number
WO2003097846A1
WO2003097846A1 PCT/EP2003/005047 EP0305047W WO03097846A1 WO 2003097846 A1 WO2003097846 A1 WO 2003097846A1 EP 0305047 W EP0305047 W EP 0305047W WO 03097846 A1 WO03097846 A1 WO 03097846A1
Authority
WO
WIPO (PCT)
Prior art keywords
genes
recombinant poxvirus
recombinant
virus
gene
Prior art date
Application number
PCT/EP2003/005047
Other languages
French (fr)
Inventor
Paul Howley
Sonja Leyrer
Original Assignee
Bavarian Nordic A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020107021891A priority Critical patent/KR101138067B1/en
Priority to DK03735384T priority patent/DK1506301T3/en
Priority to EP20030735384 priority patent/EP1506301B1/en
Priority to AU2003236646A priority patent/AU2003236646B2/en
Priority to CN038111063A priority patent/CN1653183B/en
Priority to BR0310051A priority patent/BR0310051A/en
Priority to CA2481799A priority patent/CA2481799C/en
Priority to MXPA04011194A priority patent/MXPA04011194A/en
Priority to KR1020047018293A priority patent/KR101005630B1/en
Priority to EA200401506A priority patent/EA012160B1/en
Priority to US10/510,189 priority patent/US7338662B2/en
Priority to IL16417703A priority patent/IL164177A0/en
Application filed by Bavarian Nordic A/S filed Critical Bavarian Nordic A/S
Priority to JP2004506501A priority patent/JP4693092B2/en
Priority to NZ536502A priority patent/NZ536502A/en
Publication of WO2003097846A1 publication Critical patent/WO2003097846A1/en
Priority to NO20044940A priority patent/NO334273B1/en
Priority to HK05108644A priority patent/HK1076642A1/en
Priority to US11/985,510 priority patent/US9109233B2/en
Priority to IL193087A priority patent/IL193087A/en
Priority to IL19308808A priority patent/IL193088A/en
Priority to US12/339,743 priority patent/US20100173388A1/en
Priority to US12/894,589 priority patent/US20110053260A1/en
Priority to US12/894,550 priority patent/US20110053259A1/en
Priority to NO20111324A priority patent/NO20111324A1/en
Priority to US13/371,580 priority patent/US20120178157A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a recombinant poxvirus capable of expressing two or more homologous foreign genes. Said genes are heterologous to the viral genome, but homologous in comparison to each other. The genes are especially derived from closely related variants or subtypes of a microorganism.
  • the invention further relates to a method for preparing such recombinant poxvirus and to the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting, preferably inducing, an immune response in a living animal, including a human, is provided.
  • Every living organism is constantly challenged by infectious or pathogenous agents such as bacteria, viruses, fungi or parasites .
  • infectious or pathogenous agents such as bacteria, viruses, fungi or parasites .
  • the so-called immune system prevents the organism from permanent infections, diseases or intoxination caused by such agents .
  • the immune system of a mammal can be divided into a specific and an unspecific part although both parts are closely cross-linked.
  • the unspecific immune response enables an immediate defense against a wide variety of pathogenic substances or infectious agents.
  • the specific immune response is raised after a lag phase, when the organism is challenged with a substance for the first time.
  • This specific immune response is mainly based on the production of antigen-specific antibodies and the generation of macrophages and lymphocytes, e.g. cytotoxic T-cells (CTL) .
  • CTL cytotoxic T-cells
  • the specific immune response is responsible for the fact that an individual who recovers from a specific infection is protected against this specific infection but still is susceptible for other infectious diseases.
  • a second infection with the same or a very similar infectious agent causes much milder symptoms or no symptoms at all. This so-called immunity persists for a long time, in some cases even lifelong.
  • the underlying effect is often referred to as immunological memory, which can be used for vaccination proposes
  • vaccination a method is described, where an individual is challenged with a harmless, partial or inactivated form of the infectious agent to affect, preferably induce, an immunological response in said individual, which leads to long lasting - if not lifelong - immunity against the specific infectious agent.
  • Variola virus belongs to the family of Poxviridae, a large family of complex DNA viruses that replicate in the cytoplasma of vertebrate and invertebrate cells.
  • the family of Poxviridae can be divided into the two subfamilies Chordopoxvirinae and Entomopoxvirinae based on vertebrate and insect host range.
  • the Chordopoxvirinae comprise beside others the genera of Orthopoxviruses and Avipoxviruses (Fields Virology, ed. by Fields B.N., Lippincott-Raven Publishers, 3 rd edition 1996, ISBN: 0- 7817-0253-4, Chapter 83) .
  • the genera of Orthopoxviruses comprises variola virus, the causative agent of human smallpox, and also other viruses with economical importance, e.g.
  • Vaccinia virus is the name given to the agent that was used at least the last 100 years for the vaccination against smallpox. It is not known whether W is a new species derived from cowpox or variola virus by prolonged serial passages, the living representative of a now extinct virus or maybe a product of genetic recombination. Additionally, in course of the W history, many strains of Vaccinia have arisen. These different strains demonstrate varying immunogenici y and are implicated to varying degrees with potential complications, the most serious of which is post-vaccinial encephalitis. However, many of these strains were used for the vaccination against smallpox.
  • strains NYCBOH, Western Reserve or Wyeth were used primarily in US, while the strain Ankara, Bern, Copenhagen, Lister and MVA were used for vaccination in Europe.
  • the WHO finally declared the successful eradication of variola virus .
  • Orthopoxviruses which is also the reason why W became one of the most intensively characterized viruses (Fields Virology, ed. by Fields B.N., Lippincott-Raven Publishers, 3 rd edition 1996, ISBN: 0-7817-0253-4, Chapter 83 and 84) .
  • the basic technique for inserting foreign genes into live infectious poxvirus involves recombination between pox DNA sequences flanking a foreign genetic element in a donor plasmid and homologous sequences present in the rescuing poxvirus .
  • Genetic recombination is, in general, the exchange of homologous sections of DNA between two strands of DNA. In certain viruses RNA may replace DNA.
  • Homologous sections of nucleic acid are sections of nucleic acid (DNA or RNA) , which have the same sequence of nucleotide bases. Genetic recombination may take place naturally during the replication or manufacture of new viral genomes within an infected host cell.
  • genetic recombination between viral genes may occur during the viral replication cycle that takes place in a host cell, which is co-infected with two or more different viruses or other genetic constructs.
  • a section of DNA from a first genome is used interchangeably in constructing the section of the genome of a second co-infecting virus in which the DNA is homologous with that of the first viral genome.
  • HBsAg Hepatitis B virus surface antigen
  • InfHA Influenza virus hemagglutinin
  • Plasmodi ⁇ m knowlesi sporozoite antigen as live vaccines for the prophylaxis of infectious diseases has been demonstrated and reviewed (Smith, et al . [1984] Biotechnology and Genetic Engineering Reviews 2, 383-407) .
  • a further advantage of W is the capacity to take up multiple foreign sequences, genes or antigens within a single W genome (Smith & Moss [1983], Gene, 25(1): 21-28). Furthermore, it has been reported that it is possible to elicit immunity to a number of heterologous infectious diseases with a single inoculation of a polyvalent vaccine (Perkus efc al . , [1985], Science, Vol. 229, 981-984). One example of the expression of various antigens by a single W is described by Bray et al .
  • a recombinant W which is capable to express three different structural proteins of Dengue virus serotype 4, namely the capsid (C) , pre-membrane (prM) , envelope (E) protein, and two non-structural proteins of Dengue virus serotype 4, namely NSl and NS2a, had the ability to protect mice against a homologous Dengue virus serotype 4 challenge (Bray et al . , [1989], Virology 2853-2856).
  • Dengue virus serotype 1 (Den-1) through Dengue virus serotype 4 (Den-4)
  • DHF Dengue haemorrhagic fever
  • DSS shock syndrome
  • Dengue vaccines which could prevent both Dengue fever (DF) , and Dengue haemorrhagic fever (DHF) and in vaccines useful to protect the vaccinated individual against infections induced by some or all mosquito-borne flaviviruses.
  • DF Dengue fever
  • DHF Dengue haemorrhagic fever
  • vaccination against one serotype does not result in a complete protection against Dengue virus infection, but only against infection with the same Dengue virus strain. Even more important, a person vaccinated against one serotype, has an increased risk of developing severe complications such as Dengue haemorrhagic fever when said person is infected from a Dengue virus strain of a different serotype.
  • a multivalent vaccine that contains antigens from all four Dengue virus serotypes is desired. So far it had been suggested to prepare multivalent vaccines by mixing a panel of recombinant W, each W encoding sequences of a different viruses (Moss, [1990] Immunology, 2, 317-327).
  • a multivalent vaccine comprises several disadvantages. Firstly, it is cumbersome to generate several independent recombinant W. Beside the separated production processes, also quality control and quality assurance is highly time consuming. Secondly, an infection with a mixture of recombinant viruses expressing different sequences always bears the risk that the infection event is not particularly well balanced.
  • the main risk is that only individual recombinants, but not all different recombinants comprised in the multivalent vaccine will infect target cells.
  • One reason might be an uneven distribution of recombinant viruses .
  • Another reason might be interferences between the different recombinant viruses while infecting single cells. Such interferences are known as phenomenon of superinfection.
  • only some antigens, but not all different antigens of the multivalent vaccine will finally be expressed from infected cells and, thus, presented to the immune system of a patient.
  • immune protection will be obtained only against some of the antigens, but is far from providing a complete immune protection against the various antigens presented or presentable by the multivalent vaccine.
  • an object of the present invention to provide a stable, effective and reliable vaccine against infectious diseases, which can be caused by more than one strain, clade, variant, subtype or serotype of said infectious disease causing microorganism.
  • the present invention is based on the idea to include into a poxvirus homologous genes derived from different strains, clades, variants, subtypes or serotypes of an infectious disease causing microorganism.
  • a poxvirus homologous genes derived from different strains, clades, variants, subtypes or serotypes of an infectious disease causing microorganism.
  • nucleic acid sequence of the same type of gene is not completely identical and not perfectly homologous, respectively, in all 4 serotypes:
  • sequence comparison (with Lasergene 4.05 Magalign, Macintosh) between the PrM genes of Dengue virus serotype 1, 2, 3 and 4 (PrMl-4) revealed a sequence identity of 66.5-72.9%, i.e., a homology of appr. 65-75%. It is assumed that differences and variations, respectively, in the genes of different subtypes of infectious disease causing microorganisms are the reasons why vaccination against one subtype does not automatically result in protection against infections with other variants of the same microorganism.
  • a recombinant poxvirus containing foreign DNA from flavivirus such as Japanese Encaphalitis Virus (JEV) , Yellow Fever Virus (YFV) and Dengue Virus
  • JEV Japanese Encaphalitis Virus
  • YFV Yellow Fever Virus
  • Dengue Virus a recombinant poxvirus containing foreign DNA from flavivirus
  • JEV Japanese Encaphalitis Virus
  • YFV Yellow Fever Virus
  • Dengue Virus Dengue Virus
  • US Patent No. 5,891,442 discloses a recombinant poxvirus containing the coding sequence for the polyprotein VP2 , VP3 and VP4 of infectious bursal disease. Said genes were fused and, thus, inserted into a single insertion site and have a homology of 41.9%-50.3%.
  • US Patent No. 6,217,882 describes a recombinant swinepox virus vector containing pseudorabies antigens gp50 and gp63 with a homology of 52.7% inserted into the same insertion site.
  • homologous genes or sequences having a homology of at least 50% are all inserted into the same or a single insertion site within the viral genome.
  • homologous genes or sequences have a homology of at least 50%, i.e., a homology of 50% - 100%, i.e., at least 50% identical nucleotide bases. Genes or sequences having a homology below 50% can be considered as being heterologous .
  • the term “homologous” or “homology” is used when genes or sequences are compared to each other, whereas the terms “foreign” gene, “exogenous” or “heterologous” sequence are used when genes or sequences are compared to the poxviral genome; i.e., said terms refer to a DNA sequence which is in nature not normally found associated with a poxvirus as used according to the invention.
  • the present invention relates to a recombinant poxvirus comprising at least two genes which are heterologous in comparison to the viral genome, but which are homologous among each other.
  • the term "genes” refers to coding sequences, which encode, e.g., proteins, polypeptides, peptides, antigens and the like. Proteins, polypeptides or peptides translated from homologous genes fulfill the same tasks and show the same functional properties. Homologous genes are regularly derived from different, but related sources or organisms. According to one embodiment of the present invention, the homology in the coding sequences is preferably 70% to 80%, more preferably 80% to 90% or 90% to 100%. Most preferred is a homology of 65% to 75%.
  • the recombinant poxvirus according to the present invention comprises the relevant genetic information in one single infectious unit or in one virus particle only, there is no risk of uneven infection and unbalanced expression of the different homologous sequences.
  • the recombinant poxvirus according to the present invention comprising and capable of expressing several closely or even closest related genes or almost identical sequences in one infected cell is particularly advantageous for the generation of multivalent vaccines.
  • the homologous genes or sequences according to the present invention can be derived from any microorganism, such as any virus except the vector virus, any bacterium, any fungus or parasite.
  • the homologous genes or sequences are derived from an infectious or pathogenic microorganism and most preferably from different strains or clades, variants, subtypes or serotypes of said microorganism.
  • strain or "clade” are technical terms, well known to the practitioner, referring to the taxonomy of microorganisms.
  • the taxonomic system classifies all so far characterised microorganisms into the hierarchic order of Families, Genera, species, strains (Fields Virology, ed. by Fields B.N., Lippincott-Raven Publishers, 4 th edition 2001) . While the criteria for the members of Family is their phylogenetic relationship, a Genera comprises all members which share common characteristics, and a species is defined as a polythetic class that constitutes a replicating lineage and occupies a particular ecological niche.
  • strain or "clade” describes a microorganism, i.e.
  • virus which shares the common characteristics, like basic morphology or genome structure and organisation, but varies in biological properties, like host range, tissue tropis , geographic distribution, attenuation or pathogen!city.
  • variants or “serotypes” further distinguishes between members of the same strain, also called subtypes, which show individual infection spectra or antigenic properties due to minor genomic variations.
  • the homologous genes or sequences are selected from viruses, preferably viruses, which belong to the genera of Flaviviruses, such as preferable - but not limited to - Dengue virus, West Nile virus or Japanese encephalitis virus; which belong to the genera of Retroviruses, such as preferable - but not limited to - Human Immunodeficiency Virus (HIV) ; which belong to the genera of Enteroviruses, such as preferable - but not limited to - Hand, Foot and Mouth disease, EV71; which belong to the genera of Rotaviruses or which belong to the genera of Orthomyxoviruses, such as preferable - but not limited to- Influenza virus.
  • viruses preferably viruses, which belong to the genera of Flaviviruses, such as preferable - but not limited to - Dengue virus, West Nile virus or Japanese encephalitis virus; which belong to the genera of Retroviruses, such as preferable - but not limited to - Human Immunodeficiency Virus (HIV
  • the homologous genes are selected from Dengue virus genes, preferably C, NS1 and/or NS2 , or preferably E, more preferably PrM. Most preferred are homologous genes derived from different serotypes of the virus, wherein said genes may be derived from one, two, three or from all of the 4 Dengue virus serotypes .
  • the homologous genes are selected from different HIV stains or clades.
  • the homologous genes are selected from the gag/pol coding sequence, more preferably from the env coding sequence or further preferably from a combination of structural and/or regulatory HIV coding sequences.
  • the vector virus suitable for the present invention is selected from the group of poxviruses, which can be easily cultured in selected host cells as, e.g., avian host cells, but which are highly replication deficient or actually not replicating in humans or human cells.
  • the poxvirus according to the present invention is selected from the group comprising canarypox viruses (Plotkin et al . [1995] Dev Biol Stand, vol 84: pp 165-170. Taylor et al . [1995] Vaccine, Vol 13. No. 6: pp 539-549), fowlpox viruses (Afonso et al . [2000] J Virol, pp 3815-3831. Fields Virology, ed. by Fields B.N., Lippincott-Raven Publishers, 4 th edition 2001, Chapter 85: page 2916), penguin pox viruses (Stannard et al .
  • canarypox viruses Plotkin et al . [1995] Dev Biol Stand, vol 84: pp 165-170. Taylor et al . [1995] Vaccine, Vol 13. No. 6: pp 539-549
  • fowlpox viruses Afonso e
  • a Vaccinia viruse is used for the generation of recombinant poxviruses comprising two or more homologous genes.
  • Vaccinia viruses may undergo homologous recombination of short homologous sequences and thereby may delete homologous sequences (Howley et al . ,
  • a vaccinia virus is the highly attenuated and host range restricted Vaccinia strain, Modified Vaccinia Ankara (MVA) (Sutter, G. et al . [1994], Vaccine 12: 1032-40).
  • MVA Modified Vaccinia Ankara
  • CVA Ankara strain of Vaccinia virus
  • CVA Vaccinia virus
  • MVA was described as highly host cell restricted (Meyer, H. et al . , J . Gen . Virol. 72, 1031-1038 [1991]).
  • a typical MVA strain is MVA 575 that has been deposited at the European Collection of Animal Cell Cultures under the deposition number ECACC V00120707.
  • the MVA-Vero strain or a derivative thereof can be used according to the present invention.
  • the strain MVA-Vero has been deposited at the European Collection of Animal Cell Cultures under the deposition number ECACC V99101431 and ECACC 01021411.
  • the safety of the MVA-Vero is reflected by biological, chemical and physical characteristics as described in the International Patent Application PCT/EP01/02703.
  • MVA-Vero has one additional genomic deletion.
  • the term "derivatives" of a virus according to the present invention refers to progeny viruses showing the same characteristic features as the parent virus but showing differences in one or more parts of its genome.
  • Still another embodiment according to the present invention uses MVA-BN.
  • MVA-BN has been deposited at the European Collection of Animal Cell Cultures with the deposition number ECACC V00083008.
  • MVA-BN or a derivative thereof a particular safe virus vaccine is generated, since it has been shown that the MVA-BN virus is an extremely high attenuated virus, derived from Modified Vaccinia Ankara virus. Therefore, in the most preferred embodiment, MVA-BN or derivatives thereof containing two or more homologous genes according to the present invention is used as viral vector.
  • the term "derivative of MVA-BN" describes a virus, which has the same functional characteristics compared to MVA-BN.
  • MVA-BN The features of MVA-BN, the description of biological assays allowing the evaluation whether an MVA is MVA-BN and a derivative thereof and methods allowing the generation of MVA-BN or derivatives thereof are described in WO 02/42480 (incorporated herein by reference) .
  • One easy way to examine a functional characteristic of MVA-BN or derivatives thereof is its attenuation and lack of replication in human HaCat cells.
  • a poxviral transcriptional control element preferably by an MVA, canary pox, fowl pox, or penguin pox transcriptional control element or most preferably a Vaccinia virus promoter.
  • Poxviral transcriptional control elements according to the present invention comprise furthermore every transcriptional control element functional in a poxviral system.
  • the insertion of the exogenous sequences according to the present invention is preferably directed into a non- essential region of the virus genome. Non-essential regions are e.g. loci or open reading frames (ORF) of poxviral genes, which are non-essential for the poxviral life cycle.
  • intergenic regions which describe the space inbetween two ORF, are considered as non-essential regions according to the present invention.
  • the exogenous sequences are inserted at a naturally occurring deletion site of the MVA genome (disclosed in PCT/EP96/02926 and incorporated herein by reference) .
  • the orientation of the inserted DNA does not have an influence on the functionality or stability of the recombinant virus according the present invention.
  • the present invention also provides a pharmaceutical composition and also a vaccine for inducing an immune response in a living animal body, including a human.
  • the pharmaceutical composition may generally include one or more pharmaceutically acceptable and/or approved carriers, additives, antibiotics, preservatives, adjuvants, diluents and/or stabilizers.
  • auxiliary substances can be water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, or the like.
  • Suitable carriers are typically large, slowly metabolized molecules such as proteins, polysaccharides, polylactic acids, polyglycollic acids, polymeric amino acids, aminc acid copolymers, lipid aggregates, or the like.
  • the recombinant poxvirus according to the invention is converted into a physiologically acceptable form. This can be done based on the experience in the preparation of poxvirus vaccines used for vaccination against smallpox (as described by Stickl, H. et al . [1974] Dtsch. med. Wschr . 99, 2386-2392) .
  • the purified virus is stored at -80°C with a titre of 5xlOE8 TCID 50 /ml formulated in about lOmM Tris, 140 mM NaCl pH 7.4.
  • the vaccine shots can be produced by stepwise freeze-drying of the virus in a formulation.
  • This formulation can contain additional additives such as mannitol, dextran, sugar, glycine, lactose or polyvinylpyrrolidone or other aids such as antioxidants or inert gas, stabilizers or recombinant proteins (e.g. human serum albumin) suitable for in vivo administration.
  • the glass ampoule is then sealed and can be stored between 4°C and room temperature for several months. However, as long as no need exists the ampoule is stored preferably at temperatures below -20°C.
  • the lyophilisate can be dissolved in 0.1 to 0.5 ml of an aqueous solution, preferably physiological saline or Tris buffer, and administered either systemically or locally, i.e. parenteral, subcutaneous, intravenous, intramuscular, by scarification or any other path of administration know to the skilled practitioner.
  • aqueous solution preferably physiological saline or Tris buffer
  • the mode of administration, the dose and the number of administrations can be optimized by those skilled in the art in a known manner. However, most commonly a patient is vaccinated with a second shot about one month to six weeks after the first vaccination shot.
  • the recombinant virus according to the present invention is used for the introduction of the exogenous coding sequences into a target cell .
  • the introduction of an exogenous coding sequence into a target cell may be used to produce in vi tro proteins, polypeptides, peptides, antigens and epitopes, respectively.
  • the method for introduction of a homologous or of a heterologous sequence into cells may be applied for in vi tro and in vivo therapy.
  • isolated cells that have been previously (ex vivo) infected with the recombinant poxvirus according to the invention are administered to the living animal body for inducing an immune response.
  • the recombinant poxvirus according to the invention is directly administered to the living animal body for inducing an immune response.
  • the cells surrounding the site of inoculation are directly infected in vivo by the virus or its recombinant according to the invention.
  • the cells synthesize the proteins, polypeptides, peptides or antigens, which are encoded in the exogenous coding sequences and, subsequently, present them or parts thereof on the cellular surface.
  • Specialized cells of the immune system recognize the presentation of such foreign proteins, polypeptides, peptides, antigens and epitopes and launch a specific immune response.
  • Vaccinia viral vector describes techniques and know-how for the handling, manipulation and genetic engineering of MVA.
  • the DNA sequence to be inserted into the virus may be placed into an E. coli plasmid construct into which DNA homologous to a section of DNA of the poxvirus has been inserted. Seperately, the DNA sequence to be inserted is ligated to a promoter.
  • the promoter-gene linkage is positioned in the plasmid construct so that the promoter- gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA containing a non- essential locus.
  • the resulting plasmid construct is amplified by growth within E. coli bacteria and isolated.
  • the isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g., chicken embryo fibroblasts (CEFs) , along with the poxvirus. Recombination between homologous pox DNA in the plasmid and the viral genome, respectively, gives a poxvirus modified by the presence of foreign DNA sequences .
  • a cell culture e.g., chicken embryo fibroblasts (CEFs)
  • CEFs chicken embryo fibroblasts
  • a cell of a suitable cell culture as, e.g., CEF cells is infected with a poxvirus.
  • the infected cell is, subsequently, transfected with a first plasmid vector comprising the foreign gene, preferably under the transcriptional control of a poxvirus expression control element.
  • the plasmid vector also comprises sequences capable of directing the insertion of the exogenous sequence into a selected part of the poxviral genome.
  • the plasmid vector contains also a cassette comprising a marker and/or selection gene operably linked to a poxviral promoter.
  • Suitable marker or selection genes are, e.g., the genes encoding the Green Fluorescent Protein, ⁇ -Galactosidase, neomycin, phosphoribosyltransferase or other markers.
  • the use of selection or marker cassettes simplifies the identification and isolation of the generated recombinant poxvirus.
  • a recombinant poxvirus can also be identified by PCR technology.
  • a further cell is infected with the recombinant poxvirus obtained as described above and transfected with a second vector comprising a gene, which is homologous to the gene included in the first vector.
  • the second vector also differs in the sequence directing the integration of the homologous gene into the genome of the poxvirus.
  • the recombinant virus comprising two homologous genes can be isolated.
  • the steps of infection and transfection are repeated by using the recombinant virus isolated in previous steps for infection and by using a further vector comprising a further homologous gene for transfection.
  • a suitable cell may at first be transfected by the plasmid vector comprising the foreign gene and, then, infected with the poxvirus.
  • each homologous gene into different viruses, coinfect a cell with all the obtained recombinant viruses and screen for a recombinant including all homologous genes.
  • the invention further provides a kit comprising two or more plasmid vector constructs capable of directing the integration of expressable, homologous genes into the poxvirus genome. Beside a suitable cloning site such plasmid vectors comprise sequences capable of directing the insertion of the exogenous sequence to selected parts in the poxviral genome.
  • such vectors comprise selection or marker gene cassettes .
  • the kit further comprises means and instructions to select viruses, which are recombinant for one or several of the homologous genes and optionally a selection or marker gene, inserted via said vector constructs.
  • the invention includes DNA sequences or parts thereof derived from or homologous to the recombinant poxvirus of the present invention. Such sequences comprise at least part of the exogenous sequence comprising at least a fragment of one of the homologous gene according to the present invention and at least a fragment of the genomic poxvirus sequence according to the present invention, said genomic poxvirus sequences preferably flanking the exogenous sequence.
  • Such DNA sequences can be used to identify or isolate the virus or its derivatives, e.g. by using them to generate PCR-primers, hybridization probes or in array technologies.
  • Insertion plasmid vector constructs indicating the name of the vector, its size and the localization of the sequences of interest such as:
  • AmpR ampicillin resistance gene
  • bfp blue florescence protein gene
  • dA deletion A
  • dE deletion E
  • d2 deletion 2
  • Ecogpt E. coli guanosinphosphoribosyl- transferase gene
  • EGFP enhanced green florescence protein gene
  • FI flanking sequence 1
  • F2 flanking sequence 2
  • I4L intergenic region I4L
  • IGR intergenic region
  • NPT II neomycin resistance gene
  • P poxvirus promoter
  • pr7.5 Vaccinia promoter 7.5
  • PrM pre-membrane gene of Dengue virus, number indicating from which of the four serotypes it derives
  • rpt repetition of flanking sequence.
  • Figure 10 PCR verification of the vector cloning strategies of four different insertion vectors (pBN49, pBN50, pBN40, pBN39) . Each of the plas ids was tested with 4 different PCR primer combinations. Each combination is specific for one distinct PrM sequence integrated into one distinct insertion site.
  • FIG 11 PCR verification of the recombinant poxvirus including four homologous Dengue virus PrM genes (Example 1) . While in the upper part of the gel the different PCR results of the recombinant virus are shown, the lower part provides the results of the same PCR reactions of the control plasmids as indicated.
  • the plasmids containing the homologous sequences are named pBN39, pBN49 or pBN50.
  • PrM stands for the inserted pre-membrane genes of Dengue virus, wherein the numbers indicate from which of the four serotypes it derives.
  • dA deletion A
  • dE deletion E
  • d2 deletion 2
  • I4L intergenic region I4L describes the insertion site of the exogenous DNA.
  • Figure 18 Schematic presentation of the insertion sites of three PrM genes (serotype 2-4) in the MVA genome according to Example 2.
  • Figure 19 PCR verification of the recombinant poxvirus including three homologous Dengue virus PrM genes inserted into intergenic regions (Example 2).
  • the upper panel shows the results of the PCR reactions specific for PrM2 ; the middle panel shows the results of the PCR reactions specific for PrM3 , and the lower panel shows the results of the PCR reactions specific for PrM4.
  • Lane 8 shows the same PCR reactions of the control plasmids .
  • Lane 2 shows the empty vector control MVA.
  • PrM stands for the inserted pre- membrane genes of Dengue virus, wherein the numbers indicate from which of the four serotypes it derives.
  • M Molecular weight marker.
  • a plasmid vector was constructed, which comprises about 600 bp of the flanking sequences adjacent to the deletion site A.
  • suitable PCR primers can be designed with suitable computer software (DNAsis, Hitashi software engeneering, San Bruno, USA) .
  • Such primers comprise extensions with restriction enzyme sites, which will be used to clone the flanking sequences into a vector plasmid.
  • a selection gene cassette is introduced, e.g a NPT II gene (neomycin resistance) under the transcriptional control of a poxviral promoter. Additionally, there is a cloning site for the insertion of additional genes or exogenous sequences to be inserted into deletion site A.
  • Figure 2 pBNXlO
  • a vector was constructed, which comprises about 600 bp of the flanking sequences adjacent to the deletion site E.
  • the vector is designed and constructed like described above.
  • an EGFP gene green fluorescence protein, Clonetech
  • Figure 3 pBNX32
  • Insertion vector for deletion 2 For the insertion of exogenous sequences into the MVA genome at the so-called deletion 2, corresponding with the genome position 20718-20719, a vector was constructed, which comprises about 600 bp of the flanking sequences adjacent to the deletion site 2. The vector is designed and constructed like described above. In between the flanking sequences is located an hbfp gene (humanized blue fluorescing protein, Pavalkis GN et al . ) under the transcriptional control of a poxviral promoter. Additionally, there is a cloning site for the insertion of additional genes or sequences to be inserted into deletion site 2.
  • Figure 4 pBNX36
  • a vector was constructed, which comprises about 600 bp of the flanking sequences adjacent to the intergenetic region at the I4L locus.
  • the vector is designed and constructed like described above.
  • an Ecogpt gene or gpt stands for phosphoribosyl- transferase gene isolated from E. coli
  • Figure 5 pBNX39
  • each vector contains - as described in details above - sequences homologous to the MVA genome for targeting insertion by homologous recombination. Additionally each vector contains a selection- or reporter gene cassette.
  • the PrM sequences of the four Dengue virus serotypes were synthetically made by oligo annealing and PCR amplification.
  • the PrM sequences were cloned downstream of poxvirus promoter elements to form an expression cassette.
  • This expression cassette was, then, cloned into the cloning site of the relevant insertion vector constructs .
  • the insertion vector construct for deletion A contained the PrM gene of Dengue virus serotype 2 ( Figure 6
  • the insertion vector construct for deletion 2 contained the PrM gene of Dengue virus serotype 1 ( Figure 7
  • the insertion vector construct for intergenic region I4L contained the PrM gene of Dengue virus serotype
  • the insertion vector construct for deletion E contained the PrM gene of Dengue virus serotype
  • PCR assays were performed.
  • the selected primer pairs are a combination of a primer specifically binding to the specific flanking sequence relative to the insertion site and a second primer specifically binding to one of the highly homologous Dengue virus PrM genes .
  • the insertion vector for deletion A containing the PrM gene of Dengue virus serotype 2 was screened with the Primers OBN93 (CGCGGATCCATGCTGAACATCTTGAACAGGAGACGCAGA. SEQ ID NO . : 1) and OBN477 (CATGATAAGAGATTGTATCAG. SEQ ID NO . : 2) .
  • the insertion vector for deletion 2 containing the PrM gene of Dengue virus serotype 1 was screened with the Primers OBN194
  • the insertion vector for intergenic region I4L containing the PrM gene of Dengue virus serotype 3 was screened with the Primers oBN255 (CCTTAATCGAATTCTCATGTCATGGATGGGGTAACCAGCATTAATAGT. SEQ ID NO.: 5) and OBN479 (GCTCCCATTCAATTCACATTGG. SEQ ID NO . : 6).
  • the insertion vector for deletion E containing the PrM gene of Dengue virus serotype 4 was screened with the Primers OBN210 (ATCCCATTCCTGAATGTGGTGTTAAAGCTACTGAGCGCTTCTCTCGTCTCCGTTCTCC GCTCTGGGTGCATGTCCCATAC . SEQ ID NO.: 7) and OBN478 (GTACATGGATGATATAGATATG. SEQ ID NO.: 8).
  • PCR experiments are performed in a Thermal cycler GeneAmp 9700 (Perkin Elmer) using the Tag DNA Polymerase Kit containing lOx PCR buffer, MgCl buffer and Tag DNA polymerase (Roche, Cat.no. 201205) or equivalent.
  • the PCR reactions were prepared with a total reaction volume of 50 ⁇ l containing 45 ⁇ l mastermix, the sample DNA and ddH 2 0 as required.
  • the mastermix should be prepared with 30.75 ⁇ l DdH 2 0, 5 ⁇ l lOx buffer, 1 ⁇ l dNTP- mix (10 mM each), 2.5 ⁇ l of each primer (5 pmol/ ⁇ l) , 3 ⁇ l MgCl 2 (25 mM) and 0.25 ⁇ l Taq-polymerase (5 U/ ⁇ l) .
  • the amplification was performed using the following programme :
  • the elongation time should at least be Imin/kb.
  • the PCR results shown in Figure 10 demonstrate the specifity of the primer combinations used for the single insertions .
  • the primer combination oBNl94/oBN476 is specific for deletion 2 and PrMl as insert.
  • the expected PCR fragment of plasmid pBN49 has a size of 678 bp (shown in lane 3, upper part of the gel) .
  • the primer combination oBN255/oBN479 is specific for intergenic region I4L and PrM3 as insert.
  • the expected PCR fragment of plasmid pBN50 has a size of 825 bp (shown in lane 9, upper part of the gel) .
  • the primer combination oBN210/oBN478 is specific for deletion E and PrM4 as insert.
  • the expected PCR fragment of plasmid pBN40 has a size of 607 bp (shown in lane 5, lower part of the gel) .
  • the primer combination oBN93/oBN477 is specific for deletion A and PrM2 as insert.
  • the expected PCR fragment of plasmid pBN39 has a size of 636 bp (shown in lane 11, lower part of the gel) .
  • a recombinant MVA For expression of foreign genes by a recombinant MVA, these genes have to be inserted into the viral genome by a process called homologous recombination.
  • the foreign gene of interest had been cloned into an insertion vector, as described above.
  • This vector has to be transfected after infection of cells with MVA-BN. The recombination will take place in the cellular cytoplasm of the infected and transfected cells .
  • the selection and/or reporter cassette which is also contained in the insertion vector, cells comprising recombinant viruses are identified and isolated. Homologous recombination
  • BHK (Baby hamster kidney) cells or CEF (primary chicken embryo fibroblasts) cells are seeded in 6 well plates using DMEM (Dulbecco's Modified Eagles Medium, Gibco BRL) + 10% fetal calf serum (FCS) or VP-SFM (Gibco BRL) + 4mmol/l L-Glutamine for a serum free production process.
  • DMEM Dulbecco's Modified Eagles Medium, Gibco BRL
  • FCS fetal calf serum
  • VP-SFM Zibco BRL
  • the MVA stock is diluted in DMEM/FCS or VP- SFM/L-Glutamine so that 500 ⁇ l dilution contain an appropriate amount of virus that will give a moi of 0.01.
  • Cells are assumed to be divided once after seeding. The medium is removed from cells and cells are infected with 500 ⁇ l of diluted virus for 1 hour rocking at room temperature. The inoculum is removed and cells are washed with DMEM/VP-SFM. Infected cells are left in 1.6ml DMEM/FCS and VP-SFM/L- Glutamine respectively while setting up transfection reaction (Qiagen Effectene Kit) .
  • the "Effectene" transfection kit (Qiagen) is used.
  • a transfection mix is prepared of 1-5 ⁇ g of linearized insertion vector (total amount for multiple transfection) with buffer EC to give a final volume of 150 ⁇ l.
  • 25 ⁇ l of Effectene are added per ⁇ g DNA after vortexing stock tube and the solution is mixed thoroughly by vortexing and incubated at room temperature for 10 min.
  • 600 ⁇ l of DMEM/FCS and VP- SFM/L-Glutamine respectively, are added, mixed and subsequently, the whole transfection mix is added to the cells, which are already covered with medium.
  • the cells are scraped into medium, then the cell suspension is transferred to an adequate tube and frozen at -20°C for short-term storage or at -80°C for long term storage.
  • cells were infected with MVA-BN according to the above-described protocol and were additionally transfected with insertion vector pBN40 containing the PrM gene of Dengue virus serotype 4 and as reporter gene the EGPF gene. Since the transfected vector contains a reporter gene, EGFP, the synthesized protein is detectable latest on day three in cells infected with a recombinant virus. Resulting recombinant viruses have to be purified by plaque purification.
  • infected cells fluorescing or stained
  • a pipet tip For plaque purification infected cells (fluorescing or stained) are isolated with a pipet tip, resuspended and aspirated in 200 ⁇ l PBS or medium. Then a fresh culture dish containing about 10E6 cells is infected with lOO ⁇ l of the resuspended plaques. After 48h cells are taken up in 300 ⁇ l PBS. DNA is extracted from suspension and screened with PCR analysis. A clone that shows the expected bands is chosen and fresh 6-well plates are infected with different amounts of this virus . Overlaying the wells with 1% agarose avoids further spreading of virus. After 48h infected cells comprising a recombinant virus clone are isolated.
  • MVA-PrM4 plaque purification recombinant viruses
  • MVA-PrM4/PrM2 were identified by PCR assays using a primer pair selectively amplifying the expected insertion (oBN93 and oBN477, as described above) and as control a primer pair specifically recognizing the insertion site deletion A (oBN477: as described above) and OBN452 : GTTTCATCAGAAATGACTCCATGAA , SEQ ID NO.: 11). Additionally also insertion of PrM4 into deletion E is verified with the primer pairs: OBN210 - OBN478 and OBN453 - OBN454.
  • cells were infected with MVA-BN according to the above described protocol and were additionally transfected with insertion vector pBN49 containing the PrM gene of Dengue virus serotype 1 and as reporter gene the hbfp, the gene for humanized blue fluorescing protein.
  • the synthesized hbfp protein is detectable on day three in cells infected with a recombinant virus . Resulting recombinant viruses were purified by plaque purification.
  • MVA-PrMl After 10 rounds of plaque purification recombinant viruses, MVA-PrMl, were identified by PCR assays using a primer pair selectively amplifying the expected insertion (oBN194 and OBN476, as described above) and as control a primer pair specifically recognizing the insertion site deletion 2 (oBN54: CGGGGTACCCGACGAACAAGGAACTGTAGCAGAGGCATC, SEQ ID NO.: 12 and OBN56: AACTGCAGTTGTTCGTATGTCATAAATTCTTTAATTAT, SEQ ID NO. : 13)
  • a first round cells were infected with MVA-BN according to the above described protocol and were additionally transfected with insertion vector pBN50 containing the PrM gene of Dengue virus serotype 3 and as reporter gene the Ecogpt gene (Ecogpt or shortened to gpt stands for phosphoribosyltransferase gene) .
  • Resulting recombinant viruses were purified by 3 rounds of plaque purification under phosphribosyltransferase metabolism selection by addition of mycophenolc acid, xanthin and hypoxanthin.
  • Mycophenolic acid (MPA) inhibits inosine monophosphate dehydrogenase and results in blockage of purine synthesis and inhibition of viral replication in most cell lines.
  • This blockage can be overcome by expressing Ecogpt from a constitutive promoter and providing the substrates xanthine and hypoxanthine .
  • Resulting recombinant viruses, MVA-PrM3 were identified by PCR assays using a primer pair selectively amplifying the expected insertion (oBN255 and OBN479, as described above) and as control a primer pair specifically recognizing the insertion site I4L (oBN499: CAACTCTCTTCTTGATTACC, SEQ ID NO.: 14 and OBN500: CGATCAAAGTCAATCTATG, SEQ ID NO . : 15).
  • the cells were infected with equal amounts of MVA-PrMl and MVA-PrM3 according to the above protocol .
  • Resulting recombinant viruses were designated MVA-PrMl/PrM3.
  • the cells were infected with equal amounts of MVA-PrMl/PrM3 and MVA-PrM2/PrM4 according to the above protocol. Plaque purification was performed under phosphribosyltransferase metabolism and neomycin selection. Recombinant viruses inducing a green and blue flourescence were isolated and analyzed by PCR using the primer pairs (oBN255 and OBN479. OBN499 and OBN500. OBN194 and oBN476. oBN54 and oBN56. OBN93 and oBN477. oBN477 and OBN452. OBN210 and oBN478. OBN453 and OBN454 as described above) .
  • the primer combination oBN210/oBN478 is specific for deletion E and PrM4 as insert.
  • the expected PCR fragment of the recombinant virus and the plasmid pBN40 has a size of 607 bp (shown in lane 2) .
  • the primer combination oBN453/oBN454 is specific for deletion E.
  • the expected PCR fragment of the recombinant virus is 2.7 kb, the expected band of the wild-type virus 2.3 kb (shown in lane 3) .
  • a band specific for a wild-type virus can be identified. This means that the recombinant virus preparation is not yet completely free of wild-type virus. Further plaque purification is necessary.
  • the primer combination oBN93/oBN477 is specific for deletion A and PrM2 as insert.
  • the expected PCR fragment of the recombinant virus and the plasmid pBN39 has a size of 636 bp (shown in lane 4) .
  • the primer combination oBN477/oBN452 is specific for deletion A.
  • the expected PCR fragment of the recombinant virus is 4.1 kb, the expected band of the wild-type virus 2.7 kb (shown in lane -5) . In the upper part of the gel a band specific for a wild-type virus can be identified.
  • the primer combination oBN255/oBN479 is specific for intergenic region I4L and PrM3 as insert .
  • the expected PCR fragment of the recombinant virus and the plasmid pBN50 has a size of 825 bp (shown in lane 6) .
  • the primer combination oBN499/oBN500 is specific for the intergenic region of I4L.
  • the expected PCR fragment of the recombinant virus is 1.0 kb, the expected band of the wild- type virus 0.3 kb (shown in lane 7) .
  • the primer combination oBN194/oBN476 is specific for deletion 2 and PrMl as insert.
  • the expected PCR fragment of the recombinant virus and the plasmid pBN49 has a size of 678 bp (shown in lane 8) .
  • the primer combination oBN54/oBN56 is specific for deletion 2.
  • the expected PCR fragment of the recombinant virus is 1.6 kb, the expected band of the wild-type virus 0.9 kb (shown in lane 9) .
  • a band specific for a wild-type virus can be identified.
  • a plasmid vector was constructed which comprises about 600 bp of the flanking sequences adjacent to the insertion site.
  • suitable PCR primers can be designed. Such primers comprise extensions with restriction enzyme sites, which will be used to clone the flanking sequences into a vector plasmid.
  • a selection gene cassette is introduced, e.g. NPT II gene (neomycine resistance) under the transcriptional control of a poxviral promoter (P) .
  • NPT II gene neomycine resistance
  • P poxviral promoter
  • a cloning site for the insertion of additional genes or exogenous sequences to be inserted into IGR 136-137 (Pad) One such vector construct according to the present invention is disclosed in Fig. 12 (pBNX67) .
  • a plasmid vector was constructed which comprises about 600 bp of the flanking sequences adjacent to the insertion site.
  • suitable PCR primers can be designed. Such primers comprise extensions with restriction enzyme sites, which will be used to clone the flanking sequences into a vector plasmid.
  • a selection gene cassette is introduced, e.g., Ecogpt gene (Guanin- Phosphoribosyltransferase) under the transcriptional control of a poxviral promoter (P) .
  • Ecogpt gene Guanin- Phosphoribosyltransferase
  • P poxviral promoter
  • a plasmid vector was constructed which comprises about 600 bp of the flanking sequences adjacent to the insertion site.
  • suitable PCR primers can be designed. Such primers comprise extensions with restriction enzyme sites, which will be used to clone the flanking sequences into a vector plasmid.
  • a selection gene cassette is introduced, e.g., NPT II gene (neomycine resistance) under the transcriptional control of a poxviral promoter (P) .
  • each vector contains - as described in detail above - sequences homologous to the MVA genome for targeting insertion by homologous recombination. Additionally each vector contains a selection and reporter gene cassette.
  • the PrM sequences of three Dengue virus serotypes were synthetically made as described in Example 1.
  • the insertion vector construct for IGR136-137 contained the PrM of Dengue virus serotype 4 (Fig. 15 - pBN27) .
  • the insertion vector construct for IGR 07-08 contained the PrM of Dengue virus serotype 2 (Fig. 16 - pBN34)
  • the insertion vector construct for IGR 44-45 contained the PrM of Dengue virus serotype 3 (Fig. 17 - pBN47) .
  • cells were infected with MVA-BN according to the above-described protocol and were additionally transfected with the insertion vector pBN27 containing the PrM gene of Dengue virus serotype 4 and as a reporter gene the EGFP gene. Since the transfected vector contains a reporter gene, EGFP, the synthesized protein is detectable latest on day three in cells infected with a recombinant virus. Resulting recombinant viruses have to be purified by plaque purification as described in Example 1.
  • MVA- PrM4 After four rounds of plaque purification recombinant viruses, MVA- PrM4 , were identified by PCR assays using a primer pair selectively amplifying the insertion site IGR136-137 (0BNIOO8: gataccgatcacgttcta. SEQ ID NO.: 16; and OBN1009 ggatatgattatgtagag. SEQ ID NO.: 17).
  • Cells were infected with MVA-PrM4 according to the above- described protocol and were additionally transfected with the insertion vector pBN34 containing the PrM gene of Dengue virus serotype 2 and as a reporter gene the BFP gene. Since the transfected vector contains a reporter gene, BFP, the synthesized protein is detectable latest on day three in cells infected with a recombinant virus. Resulting recombinant viruses have to be purified by plaque purification as described in Example 1. After six rounds of plaque purification recombinant virus MVA-PrM4+PrM2 was further passaged and amplified and a crude stock was prepared.
  • the recombinant was identified by PCR assays using a primer pair selectively amplifying the insertion site IGR07-08 (oBN 903: ctggataaatacgaggacgtg. SEQ ID NO.: 18; and OBN904: gacaattatccgacgcaccg; SEQ ID NO.: 19).
  • Cells were infected with MVA-PrM2+4 according to the above- described protocol and were additionally transfected with the insertion vector pBN47 containing the PrM gene of Dengue virus serotype 3 and as a reporter gene the EGFP gene. Since the transfected vector contains a reporter gene, EGFP, the synthesized protein is detectable latest on day three in cells infected with a recombinant virus. Resulting recombinant viruses have to be purified by plaque purification as described in Example 1.
  • MVA-PrM4+3+2 were identified by PCR assays using a primer pair selectively amplifying the insertion site IGR44-45 (oBN904: cgttagacaacacaccgacgatgg. SEQ ID NO.: 20; and OBN905 cggatgaaaaatttttggaag. SEQ ID NO . : 21) .
  • the PCR analysis of the recombinant virus comprising the three Dengue virus PrM genes is shown in Fig. 19. PCR experiments are performed as described in Example 1.
  • the primer combination 0BNIOO8 and OBN1009 is specific for IGR136-137, which contains the PrM4 insertion (Fig. 19, lower panel) .
  • the expected PCR fragment of the recombinant virus has a size of lkb (shown in lane 4, 5 and 6) as the plasmid positive control (lane 8) .
  • the empty vector control, devoid of PrM 4 shows the expected fragment of 190 bp (lane 2) .
  • Lane M shows the molecular weight marker and lanes 1, 3 and 7 are empty.
  • the primer combination OBN902 and OBN903 is specific for IGR07-08, which contains the PrM2 insertion (Fig. 19, upper panel) .
  • the expected PCR fragment of the recombinant virus has a size of 960bp (shown in lane 4-6) as the plasmid positive control (lane 8) .
  • the empty vector control, devoid of PrM 2 shows the expected fragment of 190 bp (lane 2).
  • the primer combination OBN904 and oBN905 is specific for IGR44-45, which contains the PrM3 insertion (Fig. 19, middle panel) .
  • the expected PCR fragment of the recombinant virus has a size of 932bp (shown in lane 4-6) as the plasmid positive control (lane 8) .
  • the empty vector control, devoid of PrM 2 shows the expected fragment of 185 bp (lane 2) .
  • the microorganism identified under I above was accompanied by:
  • Dr P J Packer Signature (s) of person (s) having the power to represent the International Depository Authority or of -authorized officials (s) :
  • Negative controls should show no sign of Cytopathic effects.
  • the Test Sample is serially diluted into in 4 wells of indicator ceil lines for each dilution. Cytopathic effects indicate that virus is present.
  • Virus titre is calculated using the below equation where x is the value obtained from a standard TCID 50 Table as a result of the distribution of the wells displaying less than 4 positive wells per dilution, and y is the value of the highest dilution where all 4 wells are positive:
  • TCID 50 1 x l0 1 + 0 - 50 lO- 5
  • Test Description Detection of Mycopiasma using a Vero indicator cell line and Hoechst 33258 fluorescent detection system. SOP QC/MYCO/07/05
  • Vero cells in the negative control are clearly seen as fluorescing nuclei with no cytoplasmic fluorescence.
  • Positive control ( . orale) must show evidence of mycopiasma as fluorescing nuclei plus extra nuclear fluorescence of mycopiasma DNA.
  • Positive test results appear as extra nuclear fluorescence of mycopiasma DNA.
  • Negative results show no cytoplasmic fluorescence.
  • Test Description Detection of bacteria and fungi by isolation on Tryptone Soya Broth (TSB) and in Fluid Thioglycollate Medium (FTGM). SOP QC/BF/01/02
  • test broths The criteria for a positive test is turbidity in any of the test broths. All broths should be clear for negative test result.
  • the microorganism identified under I above was accompanied by:
  • the microorganism identified under I above was accompanied by:
  • the criteria for a positive test result is evidence of mycopiasma by typical colony formation on agar. A negative result will show no such evidence.
  • Test Description Detection of Mycopiasma using a Vero indicator cell line and Hoechst 332S8 fluorescent detection systcm. SOP QCVMYCO/07/05
  • the criteria for a positive test is turbidity in any o the test broths. AH broths should be clear for negative test result.
  • Negative controls should show no sign of Cytopathic effects.
  • the Test Sample is serially diluted into in 4 wells of indicator cell lines for each dilution. Cytopathic effects indicate that virus is present.
  • Virus titre is calculated using the below equation where x is the value obtained from a standard TCID S0 Table as a result ofthe distribution ofthe wells displaying less than 4 positive wells per dilution, and y is the value of the highest dilution where all 4 wells are positive: .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing , an immune response in a living animal, including a human, is provided.

Description

Recombinant poxyirus expressing homologous genes inserted into the poxyiral genome
The present invention relates to a recombinant poxvirus capable of expressing two or more homologous foreign genes. Said genes are heterologous to the viral genome, but homologous in comparison to each other. The genes are especially derived from closely related variants or subtypes of a microorganism. The invention further relates to a method for preparing such recombinant poxvirus and to the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting, preferably inducing, an immune response in a living animal, including a human, is provided.
Background of the invention
Every living organism is constantly challenged by infectious or pathogenous agents such as bacteria, viruses, fungi or parasites . The so-called immune system prevents the organism from permanent infections, diseases or intoxination caused by such agents .
The immune system of a mammal can be divided into a specific and an unspecific part although both parts are closely cross-linked. The unspecific immune response enables an immediate defense against a wide variety of pathogenic substances or infectious agents. The specific immune response is raised after a lag phase, when the organism is challenged with a substance for the first time. This specific immune response is mainly based on the production of antigen-specific antibodies and the generation of macrophages and lymphocytes, e.g. cytotoxic T-cells (CTL) . The specific immune response is responsible for the fact that an individual who recovers from a specific infection is protected against this specific infection but still is susceptible for other infectious diseases. In general, a second infection with the same or a very similar infectious agent causes much milder symptoms or no symptoms at all. This so-called immunity persists for a long time, in some cases even lifelong. The underlying effect is often referred to as immunological memory, which can be used for vaccination proposes .
With the term vaccination a method is described, where an individual is challenged with a harmless, partial or inactivated form of the infectious agent to affect, preferably induce, an immunological response in said individual, which leads to long lasting - if not lifelong - immunity against the specific infectious agent.
The human smallpox disease is caused by Variola virus: Variola virus belongs to the family of Poxviridae, a large family of complex DNA viruses that replicate in the cytoplasma of vertebrate and invertebrate cells.
The family of Poxviridae can be divided into the two subfamilies Chordopoxvirinae and Entomopoxvirinae based on vertebrate and insect host range. The Chordopoxvirinae comprise beside others the genera of Orthopoxviruses and Avipoxviruses (Fields Virology, ed. by Fields B.N., Lippincott-Raven Publishers, 3rd edition 1996, ISBN: 0- 7817-0253-4, Chapter 83) . The genera of Orthopoxviruses comprises variola virus, the causative agent of human smallpox, and also other viruses with economical importance, e.g. camelpox, cowpox, sheeppox, goatpox, monkeypox and Vaccinia virus . All members of this genus are genetically related and have similar morphology or host range. Restriction endonuclease maps have even shown high sequence identity from up to 90% between different members of the Orthopoxviruses (Mackett & Archard, [1979], J Gen Virol, 45: 683-701).
Vaccinia virus (W) is the name given to the agent that was used at least the last 100 years for the vaccination against smallpox. It is not known whether W is a new species derived from cowpox or variola virus by prolonged serial passages, the living representative of a now extinct virus or maybe a product of genetic recombination. Additionally, in course of the W history, many strains of Vaccinia have arisen. These different strains demonstrate varying immunogenici y and are implicated to varying degrees with potential complications, the most serious of which is post-vaccinial encephalitis. However, many of these strains were used for the vaccination against smallpox. For example the strains NYCBOH, Western Reserve or Wyeth were used primarily in US, while the strain Ankara, Bern, Copenhagen, Lister and MVA were used for vaccination in Europe. As a result of the worldwide vaccination program with these different strains of W in 1980 the WHO finally declared the successful eradication of variola virus .
Today, W is mainly used as a laboratory strain, but beside this it is still considered as the prototype of
Orthopoxviruses , which is also the reason why W became one of the most intensively characterized viruses (Fields Virology, ed. by Fields B.N., Lippincott-Raven Publishers, 3rd edition 1996, ISBN: 0-7817-0253-4, Chapter 83 and 84) .
W and more recently other poxviruses have been used for the insertion and expression of foreign genes. The basic technique for inserting foreign genes into live infectious poxvirus involves recombination between pox DNA sequences flanking a foreign genetic element in a donor plasmid and homologous sequences present in the rescuing poxvirus . Genetic recombination is, in general, the exchange of homologous sections of DNA between two strands of DNA. In certain viruses RNA may replace DNA. Homologous sections of nucleic acid are sections of nucleic acid (DNA or RNA) , which have the same sequence of nucleotide bases. Genetic recombination may take place naturally during the replication or manufacture of new viral genomes within an infected host cell. Thus, genetic recombination between viral genes may occur during the viral replication cycle that takes place in a host cell, which is co-infected with two or more different viruses or other genetic constructs. A section of DNA from a first genome is used interchangeably in constructing the section of the genome of a second co-infecting virus in which the DNA is homologous with that of the first viral genome.
Successful expression of the inserted DNA genetic sequence by the modified infectious virus requires two conditions. First, the insertion should be into a nonessential region of the virus in order that the modified virus remains viable. The second condition for expression of inserted DNA is the presence of a promoter in the proper relationship to the inserted DNA. Regularly, the promoter is located upstream from the DNA sequence to be expressed. The usefulness of recombinant W expressing, e.g., Hepatitis B virus surface antigen (HBsAg) , Influenza virus hemagglutinin (InfHA) or Plasmodiυm knowlesi sporozoite antigen, as live vaccines for the prophylaxis of infectious diseases has been demonstrated and reviewed (Smith, et al . [1984] Biotechnology and Genetic Engineering Reviews 2, 383-407) .
A further advantage of W is the capacity to take up multiple foreign sequences, genes or antigens within a single W genome (Smith & Moss [1983], Gene, 25(1): 21-28). Furthermore, it has been reported that it is possible to elicit immunity to a number of heterologous infectious diseases with a single inoculation of a polyvalent vaccine (Perkus efc al . , [1985], Science, Vol. 229, 981-984). One example of the expression of various antigens by a single W is described by Bray et al . It was shown that a recombinant W, which is capable to express three different structural proteins of Dengue virus serotype 4, namely the capsid (C) , pre-membrane (prM) , envelope (E) protein, and two non-structural proteins of Dengue virus serotype 4, namely NSl and NS2a, had the ability to protect mice against a homologous Dengue virus serotype 4 challenge (Bray et al . , [1989], Virology 2853-2856).
The Dengue virus with its four serotypes, Dengue virus serotype 1 (Den-1) through Dengue virus serotype 4 (Den-4) , is one important member of the Flavivirus genus with respect to infections of humans . Dengue virus infection produces diseases that range from flu-like symptoms to severe or fatal illness, Dengue haemorrhagic fever (DHF) with shock syndrome (DSS) . Dengue outbreaks continue to be a major public health problem in densely populated areas of the tropical and subtropical regions, where mosquito vectors are abundant.
The concern over the spread of Dengue infection and other diseases induced by mosquito-borne Flaviviruses in many parts of the world has resulted in more efforts being made towards the development of Dengue vaccines, which could prevent both Dengue fever (DF) , and Dengue haemorrhagic fever (DHF) and in vaccines useful to protect the vaccinated individual against infections induced by some or all mosquito-borne flaviviruses.
While most cases of DF are manifested after the first infection by any of the four serotypes, a large percentage of DHF cases occur in subjects who are infected for the second time by a serotype, which is different from the first infecting serotype ' of Dengue virus. These observations give rise to the hypothesis that sequential infection of an individual having antibodies against one Dengue serotype by a different virus serotype at an appropriate interval may result in DHF in a certain number of cases.
Accordingly, vaccination against one serotype does not result in a complete protection against Dengue virus infection, but only against infection with the same Dengue virus strain. Even more important, a person vaccinated against one serotype, has an increased risk of developing severe complications such as Dengue haemorrhagic fever when said person is infected from a Dengue virus strain of a different serotype.
Thus, a multivalent vaccine that contains antigens from all four Dengue virus serotypes is desired. So far it had been suggested to prepare multivalent vaccines by mixing a panel of recombinant W, each W encoding sequences of a different viruses (Moss, [1990] Immunology, 2, 317-327). However, such a multivalent vaccine comprises several disadvantages. Firstly, it is cumbersome to generate several independent recombinant W. Beside the separated production processes, also quality control and quality assurance is highly time consuming. Secondly, an infection with a mixture of recombinant viruses expressing different sequences always bears the risk that the infection event is not particularly well balanced. The main risk is that only individual recombinants, but not all different recombinants comprised in the multivalent vaccine will infect target cells. One reason might be an uneven distribution of recombinant viruses . Another reason might be interferences between the different recombinant viruses while infecting single cells. Such interferences are known as phenomenon of superinfection. In this case, only some antigens, but not all different antigens of the multivalent vaccine will finally be expressed from infected cells and, thus, presented to the immune system of a patient. As a consequence, immune protection will be obtained only against some of the antigens, but is far from providing a complete immune protection against the various antigens presented or presentable by the multivalent vaccine.
In the context of a vaccine against Dengue virus infection the approach of a multivalent vaccine has the disadvantage that if the different sequences are expressed in different amounts or in an unpredictable manner, as it had been shown for the envelope protein of Dengue virus 2 (Deuble et al . , [1988], J. Virol 65: 2853), then such a vaccination is highly risky for a patient. An incomplete vaccination using a panel of recombinant Vaccinia viruses will only provide an immune protection against some, but not against all serotypes of Dengue virus. Unfortunately, in case of Dengue infection an incomplete vaccination is extremely unacceptable, since it increases the risk of lethal complications such as Dengue hemorrhagic fever.
Object of the Invention
It is, therefore, an object of the present invention to provide a stable, effective and reliable vaccine against infectious diseases, which can be caused by more than one strain, clade, variant, subtype or serotype of said infectious disease causing microorganism.
It is a further object of the present invention to provide a stable, effective and reliable vaccine against Dengue virus infections, which allows reliable vaccination against all Dengue virus serotypes.
Detailed description of the Invention
The present invention is based on the idea to include into a poxvirus homologous genes derived from different strains, clades, variants, subtypes or serotypes of an infectious disease causing microorganism. As already mentioned above, there are, for example, 4 groups, subtypes or serotypes of Dengue virus existing which are all comprising the same types of genes as, e.g., the gene encoding the capsid (C) protein, the gene encoding the pre-membrane (PrM) or envelope (E) protein. However, the nucleic acid sequence of the same type of gene is not completely identical and not perfectly homologous, respectively, in all 4 serotypes: For example, sequence comparison (with Lasergene 4.05 Magalign, Macintosh) between the PrM genes of Dengue virus serotype 1, 2, 3 and 4 (PrMl-4) revealed a sequence identity of 66.5-72.9%, i.e., a homology of appr. 65-75%. It is assumed that differences and variations, respectively, in the genes of different subtypes of infectious disease causing microorganisms are the reasons why vaccination against one subtype does not automatically result in protection against infections with other variants of the same microorganism. It was, therefore, the idea to generate a recombinant virus including closely related or homologous genes derived from different strains, clades, variants, subtypes or serotypes of an infectious disease causing microorganism. However, as also already indicated above, homologous recombination between homologous sequences occur during the viral life cycle and even takes place between sections of DNA that are not perfectly homologous. It was, thus, expected that the insertion of homologous genes in a single viral genome would result in homologous recombination and, thus, in deletions of the inserted homologous genes .
However, when generating a recombinant poxvirus comprising in its genome at least two foreign genes with a homology of at least 60%, it was unexpectedly found that said homologous genes remain stably inserted into the viral genome .
Even if homologous genes, preferably with a homology of at least 50%, are inserted into different insertion sites of the viral genome, the genes also remain stably inserted into the viral genome: In this case, it was expected that recombination events between said homologous genes would additionally result in loss of viral genes important for amplification of the virus and for the viral life cycle, respectively, i.e., it was expected that the viral life cycle would seriously be damaged. Since, additionally, the frequency of recombination is proportional to the distance between two linked genes, it was expected that frequency of recombination events between two or more homologous genes located in different insertion sites would be high and, thus, result in deletions of said genes and/or in severe interferences. Accordingly, it was extremely surprising that no recombination events occurred, but that the homologous genes remained stably inserted into the different insertion sites of the viral genome.
According to the prior art, a recombinant poxvirus containing foreign DNA from flavivirus, such as Japanese Encaphalitis Virus (JEV) , Yellow Fever Virus (YFV) and Dengue Virus, are known (US Patent No. 5,514,375) . However, each gene derived from said flaviviruses were inserted only a single time and into the same insertion site. Additionally, sequence comparison with a suitable computer software (Lasergene 4.05 Megalign, Macintosh) revealed a homology of the genes inserted into the poxviral genome and derived from JEV of 20.2%-29.6%, from YFV of 29.2%-45.3%, and from Dengue Virus of 22.8%-29.5%.
Similar disclosure applies to WO 98/13500 describing insertion of Dengue virus antigens into the same insertion site of Modified Vaccinia Virus Ankara (MVA) , especially into deletion site II. US Patent No. 5,338,683 discribes insertion of gp 13 and 14 of herpesvirus glycoprotein genes into two different insertion sites of a single recombinant poxvirus; however, both genes have a homology of 25.2% only. Sequence comparison between influenza virus haemagglutinin and nucleoprotein gene inserted into the same insertion site (deletion site III) of a Modified Vaccinia Virus Ankara (MVA) resulted in a homology of 49.1% (US Patent No. 5,676,950; Sutter et al . , [1994], Vaccine 12: 1032). US Patent No. 5,891,442 discloses a recombinant poxvirus containing the coding sequence for the polyprotein VP2 , VP3 and VP4 of infectious bursal disease. Said genes were fused and, thus, inserted into a single insertion site and have a homology of 41.9%-50.3%. Finally, US Patent No. 6,217,882 describes a recombinant swinepox virus vector containing pseudorabies antigens gp50 and gp63 with a homology of 52.7% inserted into the same insertion site.
In summary, it can be stated that according to the prior art homologous genes or sequences having a homology of at least 50% are all inserted into the same or a single insertion site within the viral genome.
According to the present invention, homologous genes or sequences have a homology of at least 50%, i.e., a homology of 50% - 100%, i.e., at least 50% identical nucleotide bases. Genes or sequences having a homology below 50% can be considered as being heterologous . In the context of the present invention, the term "homologous" or "homology" is used when genes or sequences are compared to each other, whereas the terms "foreign" gene, "exogenous" or "heterologous" sequence are used when genes or sequences are compared to the poxviral genome; i.e., said terms refer to a DNA sequence which is in nature not normally found associated with a poxvirus as used according to the invention. Accordingly, the present invention relates to a recombinant poxvirus comprising at least two genes which are heterologous in comparison to the viral genome, but which are homologous among each other. The term "genes" refers to coding sequences, which encode, e.g., proteins, polypeptides, peptides, antigens and the like. Proteins, polypeptides or peptides translated from homologous genes fulfill the same tasks and show the same functional properties. Homologous genes are regularly derived from different, but related sources or organisms. According to one embodiment of the present invention, the homology in the coding sequences is preferably 70% to 80%, more preferably 80% to 90% or 90% to 100%. Most preferred is a homology of 65% to 75%.
Since the recombinant poxvirus according to the present invention comprises the relevant genetic information in one single infectious unit or in one virus particle only, there is no risk of uneven infection and unbalanced expression of the different homologous sequences. Thus, the recombinant poxvirus according to the present invention comprising and capable of expressing several closely or even closest related genes or almost identical sequences in one infected cell is particularly advantageous for the generation of multivalent vaccines.
This advantage is particularly interesting for the development of vaccines against diseases, which can be caused by several closely related strains or serotypes of a virus, like e.g. Dengue virus. Recombinant poxviruses comprising homologous genes of different Dengue virus serotypes are described in the Examples .
The homologous genes or sequences according to the present invention can be derived from any microorganism, such as any virus except the vector virus, any bacterium, any fungus or parasite. Preferably, the homologous genes or sequences are derived from an infectious or pathogenic microorganism and most preferably from different strains or clades, variants, subtypes or serotypes of said microorganism.
The terms "strain" or "clade" are technical terms, well known to the practitioner, referring to the taxonomy of microorganisms. The taxonomic system classifies all so far characterised microorganisms into the hierarchic order of Families, Genera, species, strains (Fields Virology, ed. by Fields B.N., Lippincott-Raven Publishers, 4th edition 2001) . While the criteria for the members of Family is their phylogenetic relationship, a Genera comprises all members which share common characteristics, and a species is defined as a polythetic class that constitutes a replicating lineage and occupies a particular ecological niche. The term "strain" or "clade" describes a microorganism, i.e. virus, which shares the common characteristics, like basic morphology or genome structure and organisation, but varies in biological properties, like host range, tissue tropis , geographic distribution, attenuation or pathogen!city. The term "variants" or "serotypes" further distinguishes between members of the same strain, also called subtypes, which show individual infection spectra or antigenic properties due to minor genomic variations.
According to a further embodiment of the present invention the homologous genes or sequences are selected from viruses, preferably viruses, which belong to the genera of Flaviviruses, such as preferable - but not limited to - Dengue virus, West Nile virus or Japanese encephalitis virus; which belong to the genera of Retroviruses, such as preferable - but not limited to - Human Immunodeficiency Virus (HIV) ; which belong to the genera of Enteroviruses, such as preferable - but not limited to - Hand, Foot and Mouth disease, EV71; which belong to the genera of Rotaviruses or which belong to the genera of Orthomyxoviruses, such as preferable - but not limited to- Influenza virus. Most preferred are homologous genes derived from a Flavivirus .
According to a further preferred embodiment, the homologous genes are selected from Dengue virus genes, preferably C, NS1 and/or NS2 , or preferably E, more preferably PrM. Most preferred are homologous genes derived from different serotypes of the virus, wherein said genes may be derived from one, two, three or from all of the 4 Dengue virus serotypes .
According to still a further embodiment the homologous genes are selected from different HIV stains or clades. Preferably the homologous genes are selected from the gag/pol coding sequence, more preferably from the env coding sequence or further preferably from a combination of structural and/or regulatory HIV coding sequences. The vector virus suitable for the present invention is selected from the group of poxviruses, which can be easily cultured in selected host cells as, e.g., avian host cells, but which are highly replication deficient or actually not replicating in humans or human cells.
According to some preferred embodiments the poxvirus according to the present invention is selected from the group comprising canarypox viruses (Plotkin et al . [1995] Dev Biol Stand, vol 84: pp 165-170. Taylor et al . [1995] Vaccine, Vol 13. No. 6: pp 539-549), fowlpox viruses (Afonso et al . [2000] J Virol, pp 3815-3831. Fields Virology, ed. by Fields B.N., Lippincott-Raven Publishers, 4th edition 2001, Chapter 85: page 2916), penguin pox viruses (Stannard et al . [1998] J Gen Virol, 79, pp 1637- 1649) or derivatives thereof. Since these viruses belong to the genera of Avipoxviruses they can be easily cultured and amplified in avian cells. However, in mammalian or human cells they are replication defective, which means that essentially no or nearly no infectious progeny viruses are produced.
According to a further embodiment of the present invention a Vaccinia viruse, preferrably an attenuated Vaccinia virus, is used for the generation of recombinant poxviruses comprising two or more homologous genes.
Although it is known that Vaccinia viruses (W) may undergo homologous recombination of short homologous sequences and thereby may delete homologous sequences (Howley et al . ,
[1996], Gene 172: 233-237) the inventors provide a recombinant Vaccinia virus including homologous sequences or genes stably inserted into its genome. This finding is particularly unexpected, since according to Howely et al . already short sequences from up to 300 base pairs (bp) were sufficient to induce genomic rearrangement and deletion of homologous sequences in Vaccinia virus. The practitioner would, thus, expect that longer sequences would induce recombination events with an even higher probability. However, according to the present invention even sequences comprising complete homologous genes can be stably inserted into the genome of Vaccinia virus .
One - not limiting - example of a vaccinia virus is the highly attenuated and host range restricted Vaccinia strain, Modified Vaccinia Ankara (MVA) (Sutter, G. et al . [1994], Vaccine 12: 1032-40).' MVA has been generated by about 570 serial passages on chicken embryo fibroblasts of the Ankara strain of Vaccinia virus (CVA) (for review see Mayr, A., et al . [1975], Infection 3, 6-14). As a consequence of these long-term passages CVA deleted about 31 kilobases of its genomic sequence. The resulting virus strain, MVA, was described as highly host cell restricted (Meyer, H. et al . , J . Gen . Virol. 72, 1031-1038 [1991]). A typical MVA strain is MVA 575 that has been deposited at the European Collection of Animal Cell Cultures under the deposition number ECACC V00120707.
In another embodiment the MVA-Vero strain or a derivative thereof can be used according to the present invention. The strain MVA-Vero has been deposited at the European Collection of Animal Cell Cultures under the deposition number ECACC V99101431 and ECACC 01021411. The safety of the MVA-Vero is reflected by biological, chemical and physical characteristics as described in the International Patent Application PCT/EP01/02703. In comparison to normal MVA, MVA-Vero has one additional genomic deletion. The term "derivatives" of a virus according to the present invention refers to progeny viruses showing the same characteristic features as the parent virus but showing differences in one or more parts of its genome.
Still another embodiment according to the present invention uses MVA-BN. MVA-BN has been deposited at the European Collection of Animal Cell Cultures with the deposition number ECACC V00083008. By using MVA-BN or a derivative thereof a particular safe virus vaccine is generated, since it has been shown that the MVA-BN virus is an extremely high attenuated virus, derived from Modified Vaccinia Ankara virus. Therefore, in the most preferred embodiment, MVA-BN or derivatives thereof containing two or more homologous genes according to the present invention is used as viral vector. The term "derivative of MVA-BN" describes a virus, which has the same functional characteristics compared to MVA-BN. The features of MVA-BN, the description of biological assays allowing the evaluation whether an MVA is MVA-BN and a derivative thereof and methods allowing the generation of MVA-BN or derivatives thereof are described in WO 02/42480 (incorporated herein by reference) . One easy way to examine a functional characteristic of MVA-BN or derivatives thereof is its attenuation and lack of replication in human HaCat cells.
In a recombinant poxvirus according to the present invention the expression of the exogenous sequences is controlled preferably by a poxviral transcriptional control element, more preferably by an MVA, canary pox, fowl pox, or penguin pox transcriptional control element or most preferably a Vaccinia virus promoter. Poxviral transcriptional control elements according to the present invention comprise furthermore every transcriptional control element functional in a poxviral system. The insertion of the exogenous sequences according to the present invention is preferably directed into a non- essential region of the virus genome. Non-essential regions are e.g. loci or open reading frames (ORF) of poxviral genes, which are non-essential for the poxviral life cycle. Also intergenic regions, which describe the space inbetween two ORF, are considered as non-essential regions according to the present invention. In another embodiment of the invention, the exogenous sequences are inserted at a naturally occurring deletion site of the MVA genome (disclosed in PCT/EP96/02926 and incorporated herein by reference) .
The orientation of the inserted DNA does not have an influence on the functionality or stability of the recombinant virus according the present invention.
Since the recombinant poxvirus according to the invention is highly growth restricted and, thus, highly attenuated, it is an ideal candidate for the treatment of a wide range of mammals including humans and even immune-compromised humans. Hence, the present invention also provides a pharmaceutical composition and also a vaccine for inducing an immune response in a living animal body, including a human.
The pharmaceutical composition may generally include one or more pharmaceutically acceptable and/or approved carriers, additives, antibiotics, preservatives, adjuvants, diluents and/or stabilizers. Such auxiliary substances can be water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, or the like. Suitable carriers are typically large, slowly metabolized molecules such as proteins, polysaccharides, polylactic acids, polyglycollic acids, polymeric amino acids, aminc acid copolymers, lipid aggregates, or the like.
For the preparation of vaccines, the recombinant poxvirus according to the invention is converted into a physiologically acceptable form. This can be done based on the experience in the preparation of poxvirus vaccines used for vaccination against smallpox (as described by Stickl, H. et al . [1974] Dtsch. med. Wschr . 99, 2386-2392) . For example, the purified virus is stored at -80°C with a titre of 5xlOE8 TCID50/ml formulated in about lOmM Tris, 140 mM NaCl pH 7.4. For the preparation of vaccine shots, e.g., 10E2-10E8 particles of the virus are lyophilized in 100 ml of phosphate-buffered saline (PBS) in the presence of 2% peptone and 1% human albumin in an ampoule, preferably a glass ampoule. Alternatively, the vaccine shots can be produced by stepwise freeze-drying of the virus in a formulation. This formulation can contain additional additives such as mannitol, dextran, sugar, glycine, lactose or polyvinylpyrrolidone or other aids such as antioxidants or inert gas, stabilizers or recombinant proteins (e.g. human serum albumin) suitable for in vivo administration. The glass ampoule is then sealed and can be stored between 4°C and room temperature for several months. However, as long as no need exists the ampoule is stored preferably at temperatures below -20°C.
For vaccination or therapy the lyophilisate can be dissolved in 0.1 to 0.5 ml of an aqueous solution, preferably physiological saline or Tris buffer, and administered either systemically or locally, i.e. parenteral, subcutaneous, intravenous, intramuscular, by scarification or any other path of administration know to the skilled practitioner. The mode of administration, the dose and the number of administrations can be optimized by those skilled in the art in a known manner. However, most commonly a patient is vaccinated with a second shot about one month to six weeks after the first vaccination shot.
The recombinant virus according to the present invention is used for the introduction of the exogenous coding sequences into a target cell . The introduction of an exogenous coding sequence into a target cell may be used to produce in vi tro proteins, polypeptides, peptides, antigens and epitopes, respectively. Furthermore, the method for introduction of a homologous or of a heterologous sequence into cells may be applied for in vi tro and in vivo therapy. For in vi tro therapy, isolated cells that have been previously (ex vivo) infected with the recombinant poxvirus according to the invention are administered to the living animal body for inducing an immune response. For in vivo therapy, the recombinant poxvirus according to the invention is directly administered to the living animal body for inducing an immune response. In this case, the cells surrounding the site of inoculation are directly infected in vivo by the virus or its recombinant according to the invention. After infection, the cells synthesize the proteins, polypeptides, peptides or antigens, which are encoded in the exogenous coding sequences and, subsequently, present them or parts thereof on the cellular surface. Specialized cells of the immune system recognize the presentation of such foreign proteins, polypeptides, peptides, antigens and epitopes and launch a specific immune response. Methods to obtain recombinant poxviruses or to insert exogenous coding sequences into a poxviral genome are well known to the person skilled in the art. Additionally, the method is described in the examples and can also be deduced or completed from the following references :
Molecular Cloning-, A laboratory Manual. Second Edition. By J. Sambrook, E.F. Fritsch and T. Maniatis. Cold Spring Harbor Laboratory Press. 1989: describes techniques and know how for standard molecular biology techniques such as cloning of DNA, DNA and RNA isolation, western blot analysis, RT-PCR and PCR amplification techniques. - Virology Methods Manual . Edited by Brian WJ Mahy and
Hillar 0 Kangro . Academic Press. 1996: describes techniques for the handling and manipulation of viruses .
Molecular Virology: A Practical Approach. Edited by AJ
Davison and RM Elliott. The Practical Approach Series. IRL Press at Oxford University Press. Oxford 1993. Chapter 9:
Expression of genes by Vaccinia virus vectors.
Current Protocols in Molecular Biology. Publisher:
John Wiley and Son Inc. 1998. Chapter 16, section IV:
Expression of proteins in mammalian cells using Vaccinia viral vector: describes techniques and know-how for the handling, manipulation and genetic engineering of MVA.
For the generation of recombinant poxviruses according to the present invention different methods may be applicable: The DNA sequence to be inserted into the virus may be placed into an E. coli plasmid construct into which DNA homologous to a section of DNA of the poxvirus has been inserted. Seperately, the DNA sequence to be inserted is ligated to a promoter. The promoter-gene linkage is positioned in the plasmid construct so that the promoter- gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA containing a non- essential locus. The resulting plasmid construct is amplified by growth within E. coli bacteria and isolated. The isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g., chicken embryo fibroblasts (CEFs) , along with the poxvirus. Recombination between homologous pox DNA in the plasmid and the viral genome, respectively, gives a poxvirus modified by the presence of foreign DNA sequences .
According to a more preferred embodiment, a cell of a suitable cell culture as, e.g., CEF cells, is infected with a poxvirus. The infected cell is, subsequently, transfected with a first plasmid vector comprising the foreign gene, preferably under the transcriptional control of a poxvirus expression control element. As explained above, the plasmid vector also comprises sequences capable of directing the insertion of the exogenous sequence into a selected part of the poxviral genome. Optionally, the plasmid vector contains also a cassette comprising a marker and/or selection gene operably linked to a poxviral promoter. Suitable marker or selection genes are, e.g., the genes encoding the Green Fluorescent Protein, β-Galactosidase, neomycin, phosphoribosyltransferase or other markers. The use of selection or marker cassettes simplifies the identification and isolation of the generated recombinant poxvirus. However, a recombinant poxvirus can also be identified by PCR technology. Subsequently, a further cell is infected with the recombinant poxvirus obtained as described above and transfected with a second vector comprising a gene, which is homologous to the gene included in the first vector. In case, this gene shall be included into a different insertion site of the poxviral genome, the second vector also differs in the sequence directing the integration of the homologous gene into the genome of the poxvirus. After homologous recombination occurred, the recombinant virus comprising two homologous genes can be isolated. For introducing more than two homologous genes into the recombinant virus, the steps of infection and transfection are repeated by using the recombinant virus isolated in previous steps for infection and by using a further vector comprising a further homologous gene for transfection.
Alternatively, the steps of infection and transfection as described above are interchangeable, i.e., a suitable cell may at first be transfected by the plasmid vector comprising the foreign gene and, then, infected with the poxvirus.
As a further alternative, it is also possible to introduce each homologous gene into different viruses, coinfect a cell with all the obtained recombinant viruses and screen for a recombinant including all homologous genes. The invention further provides a kit comprising two or more plasmid vector constructs capable of directing the integration of expressable, homologous genes into the poxvirus genome. Beside a suitable cloning site such plasmid vectors comprise sequences capable of directing the insertion of the exogenous sequence to selected parts in the poxviral genome. Optionally, such vectors comprise selection or marker gene cassettes . The kit further comprises means and instructions to select viruses, which are recombinant for one or several of the homologous genes and optionally a selection or marker gene, inserted via said vector constructs. According to another further embodiment the invention includes DNA sequences or parts thereof derived from or homologous to the recombinant poxvirus of the present invention. Such sequences comprise at least part of the exogenous sequence comprising at least a fragment of one of the homologous gene according to the present invention and at least a fragment of the genomic poxvirus sequence according to the present invention, said genomic poxvirus sequences preferably flanking the exogenous sequence. Such DNA sequences can be used to identify or isolate the virus or its derivatives, e.g. by using them to generate PCR-primers, hybridization probes or in array technologies.
Short Description of the Figures Figure 1: Schematic presentation of the insertion sites of the four PrM (= pre-membrane) genes (serotype 1-4) in the MVA genome according to Example 1.
Figures 2-9 and 12-17: Insertion plasmid vector constructs indicating the name of the vector, its size and the localization of the sequences of interest such as:
AmpR = ampicillin resistance gene, bfp = blue florescence protein gene, dA = deletion A, dE = deletion E, d2 = deletion 2, Ecogpt = E. coli guanosinphosphoribosyl- transferase gene, EGFP = enhanced green florescence protein gene, FI = flanking sequence 1, F2 = flanking sequence 2, I4L = intergenic region I4L, IGR = intergenic region, NPT II = neomycin resistance gene, P = poxvirus promoter, pr7.5 = Vaccinia promoter 7.5, PrM = pre-membrane gene of Dengue virus, number indicating from which of the four serotypes it derives, rpt = repetition of flanking sequence. Figure 10: PCR verification of the vector cloning strategies of four different insertion vectors (pBN49, pBN50, pBN40, pBN39) . Each of the plas ids was tested with 4 different PCR primer combinations. Each combination is specific for one distinct PrM sequence integrated into one distinct insertion site.
Figure 11: PCR verification of the recombinant poxvirus including four homologous Dengue virus PrM genes (Example 1) . While in the upper part of the gel the different PCR results of the recombinant virus are shown, the lower part provides the results of the same PCR reactions of the control plasmids as indicated. The plasmids containing the homologous sequences are named pBN39, pBN49 or pBN50. PrM stands for the inserted pre-membrane genes of Dengue virus, wherein the numbers indicate from which of the four serotypes it derives. dA = deletion A, dE = deletion E, d2 = deletion 2, I4L = intergenic region I4L describes the insertion site of the exogenous DNA.
Figure 18: Schematic presentation of the insertion sites of three PrM genes (serotype 2-4) in the MVA genome according to Example 2.
Figure 19: PCR verification of the recombinant poxvirus including three homologous Dengue virus PrM genes inserted into intergenic regions (Example 2). The upper panel shows the results of the PCR reactions specific for PrM2 ; the middle panel shows the results of the PCR reactions specific for PrM3 , and the lower panel shows the results of the PCR reactions specific for PrM4. Lane 8 shows the same PCR reactions of the control plasmids . Lane 2 shows the empty vector control MVA. PrM stands for the inserted pre- membrane genes of Dengue virus, wherein the numbers indicate from which of the four serotypes it derives. M = Molecular weight marker.
The following examples will further, illustrate the present invention. It will be well understood by a person skilled in the art that the provided examples in no way may be interpreted in a way that limits the applicability of the technology provided by the present invention to this examples.
Example 1
Insertion vectors
Insertion vector for deletion A
For the insertion of exogenous sequences into the MVA genome at the so-called deletion A or deletion 1 respectively, corresponding to the genome position 7608- 7609, a plasmid vector was constructed, which comprises about 600 bp of the flanking sequences adjacent to the deletion site A. To isolate the flanking sequences from the genomic MVA-BN DNA, suitable PCR primers can be designed with suitable computer software (DNAsis, Hitashi software engeneering, San Bruno, USA) . Such primers comprise extensions with restriction enzyme sites, which will be used to clone the flanking sequences into a vector plasmid. In between these flanking sequences, a selection gene cassette is introduced, e.g a NPT II gene (neomycin resistance) under the transcriptional control of a poxviral promoter. Additionally, there is a cloning site for the insertion of additional genes or exogenous sequences to be inserted into deletion site A. One such vector construct according to the present invention is disclosed in Figure 2 (pBNXlO) .
Insertion vector for deletion E
For the insertion of exogenous sequences into the MVA genome at the so-called deletion E or deletion 4, respectively, corresponding with the genome position 170480-170481, a vector was constructed, which comprises about 600 bp of the flanking sequences adjacent to the deletion site E. The vector is designed and constructed like described above. In between the flanking sequences is located an EGFP gene (green fluorescence protein, Clonetech) under the transcriptional control of a poxviral promoter. Additionally, there is a cloning site for the insertion of additional genes or sequences to be inserted into deletion site A. One such vector construct according to the present invention is disclosed in Figure 3 (pBNX32) .
Insertion vector for deletion 2 For the insertion of exogenous sequences into the MVA genome at the so-called deletion 2, corresponding with the genome position 20718-20719, a vector was constructed, which comprises about 600 bp of the flanking sequences adjacent to the deletion site 2. The vector is designed and constructed like described above. In between the flanking sequences is located an hbfp gene (humanized blue fluorescing protein, Pavalkis GN et al . ) under the transcriptional control of a poxviral promoter. Additionally, there is a cloning site for the insertion of additional genes or sequences to be inserted into deletion site 2. One such vector construct according to the present invention is disclosed in Figure 4 (pBNX36) .
Insertion vector for intergenetic region, I4L
For the insertion of exogenous sequences in the intergenetic region, between the ORF I3L and I4L, corresponding to the genome position 56760, a vector was constructed, which comprises about 600 bp of the flanking sequences adjacent to the intergenetic region at the I4L locus. The vector is designed and constructed like described above. In between the flanking sequences is located an Ecogpt gene (or gpt stands for phosphoribosyl- transferase gene isolated from E. coli) under the transcriptional control of a poxviral promoter. Additionally, there is a cloning site for the insertion of additional genes or sequences to be inserted into the intergenetic region after the I4L ORF. One such vector construct according to the present invention is disclosed in Figure 5 (pBNX39) .
Construction of recombinant poxvirus comprising several homologous genes integrated in its genome.
Insertion vectors
For the insertion of the four PrM genes of the four serotypes of Dengue virus in the MVA genome four independent recombination vectors were used. These vectors contain - as described in details above - sequences homologous to the MVA genome for targeting insertion by homologous recombination. Additionally each vector contains a selection- or reporter gene cassette.
The PrM sequences of the four Dengue virus serotypes were synthetically made by oligo annealing and PCR amplification. The PrM sequences were cloned downstream of poxvirus promoter elements to form an expression cassette. This expression cassette was, then, cloned into the cloning site of the relevant insertion vector constructs . As result, the insertion vector construct for deletion A contained the PrM gene of Dengue virus serotype 2 (Figure 6
- pBN39) . The insertion vector construct for deletion 2 contained the PrM gene of Dengue virus serotype 1 (Figure 7
- pBN49 ) . The insertion vector construct for intergenic region I4L contained the PrM gene of Dengue virus serotype
3 (Figure 8 - pBN50) . The insertion vector construct for deletion E contained the PrM gene of Dengue virus serotype
4 (Figure 9 - pBN40) .
PCR verification of the insertion vectors
For verification of the cloning strategies, PCR assays were performed. For these PCR assays the selected primer pairs are a combination of a primer specifically binding to the specific flanking sequence relative to the insertion site and a second primer specifically binding to one of the highly homologous Dengue virus PrM genes .
The insertion vector for deletion A containing the PrM gene of Dengue virus serotype 2 was screened with the Primers OBN93 (CGCGGATCCATGCTGAACATCTTGAACAGGAGACGCAGA. SEQ ID NO . : 1) and OBN477 (CATGATAAGAGATTGTATCAG. SEQ ID NO . : 2) .
The insertion vector for deletion 2 containing the PrM gene of Dengue virus serotype 1 was screened with the Primers OBN194
(ATGTTGAACATAATGAACAGGAGGAAAAGATCTGTGACCATGCTCCTCATGCTGCTGC CCACAGCCCTGGCGTTCCATCT . SEQ ID NO.: 3) and OBN476 (GATTTTGCTATTCAGTGGACTGGATG. SEQ ID NO . : 4).
The insertion vector for intergenic region I4L containing the PrM gene of Dengue virus serotype 3 was screened with the Primers oBN255 (CCTTAATCGAATTCTCATGTCATGGATGGGGTAACCAGCATTAATAGT. SEQ ID NO.: 5) and OBN479 (GCTCCCATTCAATTCACATTGG. SEQ ID NO . : 6).
The insertion vector for deletion E containing the PrM gene of Dengue virus serotype 4 was screened with the Primers OBN210 (ATCCCATTCCTGAATGTGGTGTTAAAGCTACTGAGCGCTTCTCTCGTCTCCGTTCTCC GCTCTGGGTGCATGTCCCATAC . SEQ ID NO.: 7) and OBN478 (GTACATGGATGATATAGATATG. SEQ ID NO.: 8).
PCR experiments are performed in a Thermal cycler GeneAmp 9700 (Perkin Elmer) using the Tag DNA Polymerase Kit containing lOx PCR buffer, MgCl buffer and Tag DNA polymerase (Roche, Cat.no. 201205) or equivalent. In general the PCR reactions were prepared with a total reaction volume of 50 μl containing 45 μl mastermix, the sample DNA and ddH20 as required. The mastermix should be prepared with 30.75 μl DdH20, 5 μl lOx buffer, 1 μl dNTP- mix (10 mM each), 2.5 μl of each primer (5 pmol/μl) , 3 μl MgCl2 (25 mM) and 0.25 μl Taq-polymerase (5 U/μl) .
The amplification was performed using the following programme :
1) Denaturation : 4 min 94°C
2) 30 Cycles:
Denaturation : 30 sec 94°C
Annealing: 30 sec 55°C
Elongation: 1-3 min 72°C
3) Elongation 7 min 72°C
4) Store 4°C
Based on the size of the inserted gene the elongation time should at least be Imin/kb.
The PCR results shown in Figure 10 demonstrate the specifity of the primer combinations used for the single insertions . The primer combination oBNl94/oBN476 is specific for deletion 2 and PrMl as insert. The expected PCR fragment of plasmid pBN49 has a size of 678 bp (shown in lane 3, upper part of the gel) .
The primer combination oBN255/oBN479 is specific for intergenic region I4L and PrM3 as insert. The expected PCR fragment of plasmid pBN50 has a size of 825 bp (shown in lane 9, upper part of the gel) .
The primer combination oBN210/oBN478 is specific for deletion E and PrM4 as insert. The expected PCR fragment of plasmid pBN40 has a size of 607 bp (shown in lane 5, lower part of the gel) .
The primer combination oBN93/oBN477 is specific for deletion A and PrM2 as insert. The expected PCR fragment of plasmid pBN39 has a size of 636 bp (shown in lane 11, lower part of the gel) .
Generation of the recombinant MVA via homologous recombina. tion
For expression of foreign genes by a recombinant MVA, these genes have to be inserted into the viral genome by a process called homologous recombination. For that purpose, the foreign gene of interest had been cloned into an insertion vector, as described above. This vector has to be transfected after infection of cells with MVA-BN. The recombination will take place in the cellular cytoplasm of the infected and transfected cells . With help of the selection and/or reporter cassette, which is also contained in the insertion vector, cells comprising recombinant viruses are identified and isolated. Homologous recombination
For homologous recombination, BHK (Baby hamster kidney) cells or CEF (primary chicken embryo fibroblasts) cells are seeded in 6 well plates using DMEM (Dulbecco's Modified Eagles Medium, Gibco BRL) + 10% fetal calf serum (FCS) or VP-SFM (Gibco BRL) + 4mmol/l L-Glutamine for a serum free production process.
Cells need to be still in the growing phase and, therefore, should reach 60-80% confluence on the day of transfection. Cells were counted before seeding, as the number of cells has to be known for determination of the multiplicity of infection (moi) for infection.
For infection, the MVA stock is diluted in DMEM/FCS or VP- SFM/L-Glutamine so that 500 μl dilution contain an appropriate amount of virus that will give a moi of 0.01. Cells are assumed to be divided once after seeding. The medium is removed from cells and cells are infected with 500μl of diluted virus for 1 hour rocking at room temperature. The inoculum is removed and cells are washed with DMEM/VP-SFM. Infected cells are left in 1.6ml DMEM/FCS and VP-SFM/L- Glutamine respectively while setting up transfection reaction (Qiagen Effectene Kit) .
For transfection, the "Effectene" transfection kit (Qiagen) is used. A transfection mix is prepared of 1-5 μg of linearized insertion vector (total amount for multiple transfection) with buffer EC to give a final volume of 150 μl. Add 8.0 μl Enhancer per μg DNA, vortex and incubate at room temperature for 5 min. Then, 25 μl of Effectene are added per μg DNA after vortexing stock tube and the solution is mixed thoroughly by vortexing and incubated at room temperature for 10 min. 600 μl of DMEM/FCS and VP- SFM/L-Glutamine respectively, are added, mixed and subsequently, the whole transfection mix is added to the cells, which are already covered with medium. Gently the dish is rocked to mix the transfection reaction. Incubation takes place at 37°C with 5%C02 over night. The next day the medium is removed and replaced with fresh DMEM/FCS or VP- SFM/L-Glutamine . Incubation is continued until day 3.
For harvesting, the cells are scraped into medium, then the cell suspension is transferred to an adequate tube and frozen at -20°C for short-term storage or at -80°C for long term storage.
Insertion of PrM4 into MVA
In a first round, cells were infected with MVA-BN according to the above-described protocol and were additionally transfected with insertion vector pBN40 containing the PrM gene of Dengue virus serotype 4 and as reporter gene the EGPF gene. Since the transfected vector contains a reporter gene, EGFP, the synthesized protein is detectable latest on day three in cells infected with a recombinant virus. Resulting recombinant viruses have to be purified by plaque purification.
For plaque purification infected cells (fluorescing or stained) are isolated with a pipet tip, resuspended and aspirated in 200μl PBS or medium. Then a fresh culture dish containing about 10E6 cells is infected with lOOμl of the resuspended plaques. After 48h cells are taken up in 300μl PBS. DNA is extracted from suspension and screened with PCR analysis. A clone that shows the expected bands is chosen and fresh 6-well plates are infected with different amounts of this virus . Overlaying the wells with 1% agarose avoids further spreading of virus. After 48h infected cells comprising a recombinant virus clone are isolated.
This procedure is repeated until no wild-type MVA-BN can be detected in the PCR analysis. After 4 rounds of plaque purification recombinant viruses, MVA-PrM4, were identified by PCR assays using a primer pair selectively amplifying the expected insertion (oBN210 and OBN478, as described above) and as control a primer pair specifically recognizing the insertion site deletion E (OBN453: GTTGAAGGATTCACTTCCGTGGA, SEQ ID NO . : 9 and OBN454: GCATTCACAGATTCTATTGTGAGTC, SEQ ID NO. : 10)
Insertion of PrM2 into MVA-PrM4
Cells were infected with MVA-PrM4 according to the above described protocol and were additionally transfected with insertion vector pBN39 containing the PrM gene of Dengue virus serotype 2 and as selection gene the NPT II, a neomycin resistance gene. For purification of recombinant MVA expressing an antibiotic resistance gene three rounds of virus amplification under selective conditions before plaque purification are recommended. For neomycinphosphotransferase selection G418 is added to the medium. G418 is a derivative of neomycin and inhibits the protein-biosynthesis by interference with the action of the ribosomes . NPT gene activity inactivates G418 by phosphorylation.
After 16 rounds of plaque purification under neomycin selection recombinant viruses, MVA-PrM4/PrM2 , were identified by PCR assays using a primer pair selectively amplifying the expected insertion (oBN93 and oBN477, as described above) and as control a primer pair specifically recognizing the insertion site deletion A (oBN477: as described above) and OBN452 : GTTTCATCAGAAATGACTCCATGAA , SEQ ID NO.: 11). Additionally also insertion of PrM4 into deletion E is verified with the primer pairs: OBN210 - OBN478 and OBN453 - OBN454.
Insertion of PrMl into MVA
In a first round, cells were infected with MVA-BN according to the above described protocol and were additionally transfected with insertion vector pBN49 containing the PrM gene of Dengue virus serotype 1 and as reporter gene the hbfp, the gene for humanized blue fluorescing protein. The synthesized hbfp protein is detectable on day three in cells infected with a recombinant virus . Resulting recombinant viruses were purified by plaque purification. After 10 rounds of plaque purification recombinant viruses, MVA-PrMl, were identified by PCR assays using a primer pair selectively amplifying the expected insertion (oBN194 and OBN476, as described above) and as control a primer pair specifically recognizing the insertion site deletion 2 (oBN54: CGGGGTACCCGACGAACAAGGAACTGTAGCAGAGGCATC, SEQ ID NO.: 12 and OBN56: AACTGCAGTTGTTCGTATGTCATAAATTCTTTAATTAT, SEQ ID NO. : 13)
Insertion of PrM3 into MVA
In a first round, cells were infected with MVA-BN according to the above described protocol and were additionally transfected with insertion vector pBN50 containing the PrM gene of Dengue virus serotype 3 and as reporter gene the Ecogpt gene (Ecogpt or shortened to gpt stands for phosphoribosyltransferase gene) . Resulting recombinant viruses were purified by 3 rounds of plaque purification under phosphribosyltransferase metabolism selection by addition of mycophenolc acid, xanthin and hypoxanthin. Mycophenolic acid (MPA) inhibits inosine monophosphate dehydrogenase and results in blockage of purine synthesis and inhibition of viral replication in most cell lines. This blockage can be overcome by expressing Ecogpt from a constitutive promoter and providing the substrates xanthine and hypoxanthine . Resulting recombinant viruses, MVA-PrM3, were identified by PCR assays using a primer pair selectively amplifying the expected insertion (oBN255 and OBN479, as described above) and as control a primer pair specifically recognizing the insertion site I4L (oBN499: CAACTCTCTTCTTGATTACC, SEQ ID NO.: 14 and OBN500: CGATCAAAGTCAATCTATG, SEQ ID NO . : 15).
Coinfection of MVA-PrMl and MVA-PrM3
The cells were infected with equal amounts of MVA-PrMl and MVA-PrM3 according to the above protocol . After 3 rounds of plaque purification under phosphribosyltransferase metabolism selection of blue fluorescing clones of recombinant viruses were analyzed by PCR using the primer pairs (oBN255 and OBN479. oBN499 and OBN500. OBN194 and OBN476. oBN54 and OBN56 as described above). Resulting recombinant viruses were designated MVA-PrMl/PrM3.
Coinfection of MVA-PrMl / PrM3 and MVA-PrM2/PrM4
The cells were infected with equal amounts of MVA-PrMl/PrM3 and MVA-PrM2/PrM4 according to the above protocol. Plaque purification was performed under phosphribosyltransferase metabolism and neomycin selection. Recombinant viruses inducing a green and blue flourescence were isolated and analyzed by PCR using the primer pairs (oBN255 and OBN479. OBN499 and OBN500. OBN194 and oBN476. oBN54 and oBN56. OBN93 and oBN477. oBN477 and OBN452. OBN210 and oBN478. OBN453 and OBN454 as described above) .
The PCR analysis of the recombinant virus (Clone 20) comprising all four PrM genes is shown in Figure 11. While in the upper part of the gel the different PCR results of the recombinant virus are shown, the lower part provides the results of the same PCR reactions of the control plasmids (as indicated) . Lane 1, 10 and 11 show a lkb and a lOObp molecular marker.
The primer combination oBN210/oBN478 is specific for deletion E and PrM4 as insert. The expected PCR fragment of the recombinant virus and the plasmid pBN40 has a size of 607 bp (shown in lane 2) .
The primer combination oBN453/oBN454 is specific for deletion E. The expected PCR fragment of the recombinant virus is 2.7 kb, the expected band of the wild-type virus 2.3 kb (shown in lane 3) . Also in the upper part of the gel a band specific for a wild-type virus can be identified. This means that the recombinant virus preparation is not yet completely free of wild-type virus. Further plaque purification is necessary. The primer combination oBN93/oBN477 is specific for deletion A and PrM2 as insert. The expected PCR fragment of the recombinant virus and the plasmid pBN39 has a size of 636 bp (shown in lane 4) .
The primer combination oBN477/oBN452 is specific for deletion A. The expected PCR fragment of the recombinant virus is 4.1 kb, the expected band of the wild-type virus 2.7 kb (shown in lane -5) . In the upper part of the gel a band specific for a wild-type virus can be identified.
The primer combination oBN255/oBN479 is specific for intergenic region I4L and PrM3 as insert . The expected PCR fragment of the recombinant virus and the plasmid pBN50 has a size of 825 bp (shown in lane 6) .
The primer combination oBN499/oBN500 is specific for the intergenic region of I4L. The expected PCR fragment of the recombinant virus is 1.0 kb, the expected band of the wild- type virus 0.3 kb (shown in lane 7) .
The primer combination oBN194/oBN476 is specific for deletion 2 and PrMl as insert. The expected PCR fragment of the recombinant virus and the plasmid pBN49 has a size of 678 bp (shown in lane 8) .
The primer combination oBN54/oBN56 is specific for deletion 2. The expected PCR fragment of the recombinant virus is 1.6 kb, the expected band of the wild-type virus 0.9 kb (shown in lane 9) . In the upper part of the gel a band specific for a wild-type virus can be identified.
Alternatively, one can produce 4 different viruses, coinfect cells with all four viruses and screen for a recombinant .
Improvements can also be achieved with recombination vectors, which contain further selection- or resistance markers . Example 2
Insertion vectors
Recombination vector for intergenic region 136-137 (IGR 136-137)
For the insertion of exogenous sequences into the MVA genome at the so-called intergenic region (IGR) 136-137 corresponding to the genome position 129.940 a plasmid vector was constructed which comprises about 600 bp of the flanking sequences adjacent to the insertion site. To isolate the flanking sequences from the genomic MVA-BN DNA suitable PCR primers can be designed. Such primers comprise extensions with restriction enzyme sites, which will be used to clone the flanking sequences into a vector plasmid. In between this flanking sequences, a selection gene cassette is introduced, e.g. NPT II gene (neomycine resistance) under the transcriptional control of a poxviral promoter (P) . Additionally there is a cloning site for the insertion of additional genes or exogenous sequences to be inserted into IGR 136-137 (Pad) . One such vector construct according to the present invention is disclosed in Fig. 12 (pBNX67) .
Recombination vector for intergenic region 07-08 (IGR 07- 08)
For the insertion of exogenous sequences into the MVA genome in the intergenic region (IGR) 07-08 corresponding to the genome position 12.800, a plasmid vector was constructed which comprises about 600 bp of the flanking sequences adjacent to the insertion site. To isolate the flanking sequences from the genomic MVA-BN DNA suitable PCR primers can be designed. Such primers comprise extensions with restriction enzyme sites, which will be used to clone the flanking sequences into a vector plasmid. In between this flanking sequences, a selection gene cassette is introduced, e.g., Ecogpt gene (Guanin- Phosphoribosyltransferase) under the transcriptional control of a poxviral promoter (P) . Additionally, there is a cloning site for the insertion of additional genes or exogenous sequences to be inserted into IGR 07-08 (Pad) . One such vector construct according to the present invention is disclosed in Fig. 13 (pBNX88) .
Recombination vector for intergenic region 44-45 (IGR 44- 45)
For the insertion of exogenous sequences into the MVA genome at the intergenic region (IGR) 44-45 corresponding to the genome position 37.330, a plasmid vector was constructed which comprises about 600 bp of the flanking sequences adjacent to the insertion site. To isolate the flanking sequences from the genomic MVA-BN DNA suitable PCR primers can be designed. Such primers comprise extensions with restriction enzyme sites, which will be used to clone the flanking sequences into a vector plasmid. In between this flanking sequences, a selection gene cassette is introduced, e.g., NPT II gene (neomycine resistance) under the transcriptional control of a poxviral promoter (P) .
Additionally there is a cloning site for the insertion of additional genes or exogenous sequences to be inserted into IGR 44-45 (Pad) . One such vector construct according to the present invention is disclosed in Fig. 14 (pBNX87) .
Construction of recombinant poxvirus comprising several homologous genes integrated in its genome
Insertion vectors
For the insertion of the three PrM genes of serotype 2, 3 and 4 of Dengue virus in the MVA genome, three independent recombination vectors were used.
These vectors contain - as described in detail above - sequences homologous to the MVA genome for targeting insertion by homologous recombination. Additionally each vector contains a selection and reporter gene cassette.
The PrM sequences of three Dengue virus serotypes were synthetically made as described in Example 1. As result, the insertion vector construct for IGR136-137 contained the PrM of Dengue virus serotype 4 (Fig. 15 - pBN27) . The insertion vector construct for IGR 07-08 contained the PrM of Dengue virus serotype 2 (Fig. 16 - pBN34) , and the insertion vector construct for IGR 44-45 contained the PrM of Dengue virus serotype 3 (Fig. 17 - pBN47) .
Generation of the recombinant MVA via homologous recombina ti on
The generation of recombinant MVA by homologous recombination was performed as described in Example 1.
The insertion sites for the PrM4, PrM3 and PrM 2 in the MVA genome are depicted in Fig. 18. Insertion of PrM 4 into MVA
In a first round, cells were infected with MVA-BN according to the above-described protocol and were additionally transfected with the insertion vector pBN27 containing the PrM gene of Dengue virus serotype 4 and as a reporter gene the EGFP gene. Since the transfected vector contains a reporter gene, EGFP, the synthesized protein is detectable latest on day three in cells infected with a recombinant virus. Resulting recombinant viruses have to be purified by plaque purification as described in Example 1. After four rounds of plaque purification recombinant viruses, MVA- PrM4 , were identified by PCR assays using a primer pair selectively amplifying the insertion site IGR136-137 (0BNIOO8: gataccgatcacgttcta. SEQ ID NO.: 16; and OBN1009 ggatatgattatgtagag. SEQ ID NO.: 17).
Insertion of PrM 2 into MVA
Cells were infected with MVA-PrM4 according to the above- described protocol and were additionally transfected with the insertion vector pBN34 containing the PrM gene of Dengue virus serotype 2 and as a reporter gene the BFP gene. Since the transfected vector contains a reporter gene, BFP, the synthesized protein is detectable latest on day three in cells infected with a recombinant virus. Resulting recombinant viruses have to be purified by plaque purification as described in Example 1. After six rounds of plaque purification recombinant virus MVA-PrM4+PrM2 was further passaged and amplified and a crude stock was prepared. The recombinant was identified by PCR assays using a primer pair selectively amplifying the insertion site IGR07-08 (oBN 903: ctggataaatacgaggacgtg. SEQ ID NO.: 18; and OBN904: gacaattatccgacgcaccg; SEQ ID NO.: 19).
Insertion of PrM 3 into MVA
Cells were infected with MVA-PrM2+4 according to the above- described protocol and were additionally transfected with the insertion vector pBN47 containing the PrM gene of Dengue virus serotype 3 and as a reporter gene the EGFP gene. Since the transfected vector contains a reporter gene, EGFP, the synthesized protein is detectable latest on day three in cells infected with a recombinant virus. Resulting recombinant viruses have to be purified by plaque purification as described in Example 1. After three rounds of plaque purification recombinant viruses, MVA-PrM4+3+2 , were identified by PCR assays using a primer pair selectively amplifying the insertion site IGR44-45 (oBN904: cgttagacaacacaccgacgatgg. SEQ ID NO.: 20; and OBN905 cggatgaaaaatttttggaag. SEQ ID NO . : 21) .
The PCR analysis of the recombinant virus comprising the three Dengue virus PrM genes is shown in Fig. 19. PCR experiments are performed as described in Example 1. The primer combination 0BNIOO8 and OBN1009 is specific for IGR136-137, which contains the PrM4 insertion (Fig. 19, lower panel) . The expected PCR fragment of the recombinant virus has a size of lkb (shown in lane 4, 5 and 6) as the plasmid positive control (lane 8) . The empty vector control, devoid of PrM 4 shows the expected fragment of 190 bp (lane 2) . Lane M shows the molecular weight marker and lanes 1, 3 and 7 are empty. The primer combination OBN902 and OBN903 is specific for IGR07-08, which contains the PrM2 insertion (Fig. 19, upper panel) . The expected PCR fragment of the recombinant virus has a size of 960bp (shown in lane 4-6) as the plasmid positive control (lane 8) . The empty vector control, devoid of PrM 2 shows the expected fragment of 190 bp (lane 2). The primer combination OBN904 and oBN905 is specific for IGR44-45, which contains the PrM3 insertion (Fig. 19, middle panel) . The expected PCR fragment of the recombinant virus has a size of 932bp (shown in lane 4-6) as the plasmid positive control (lane 8) . The empty vector control, devoid of PrM 2 shows the expected fragment of 185 bp (lane 2) .
Figure imgf000047_0001
INDICATIONS RELATING TO ADEPOSTTED MICROORGANISM
(PCT Rule 13tø)
A. Theindicationsniadebelowrelatetothemicroorganismreferredtointhedescription onpage /[& , line jjQi
B. D3ENTO7ICATIONOFDEPOSIT Further deposits are identified on an additional sheet | |
Name of depositary institution ECACC
European Collection of Cell Cultures
Address of depositary institution (including postal code and country)
Centre for Applied Microbiology & Research Salisbury
Wiltshire SP4 OJG United Kingdom
Date of deposit Accession Number
December 7, 2000 00120707
C. ADDITIONAL INDICATIONS βeave blank if not applicable) This information is continued on an additional sheet Q
In respect of all designated States to which such action is possible and to the extent that it is legally permissable under the law of the designated State, it is requested that a sample of the deposited microorganism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation. E.g., EPC Rule 28 (4); UK Patent Rules 1995, Schedule 2, Paragraph 3; Australian Regulation 3.25(3); Danish Patents Act Sections 22 and 33(3) and generally similar provisions mutatis mutandis for any other designated State;
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (ifthe indications are notfor all designated States)
E. SEPARATE FURNISHING OF INDICATIONS (leaveblankifnotapplicable)
The indications listed below will be submitted to the International Bureau later (specify the general 'nature of "the indications e.g., "Accession Number of Deposit")
ForlnternationalBureauuse only
I J This sheet was receivedby the International Bureau on:
Authorized officer
Figure imgf000047_0002
APPENDIX 3
Page 14
BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
TO INTERNATIONAL FORM
Figure imgf000048_0001
BAVARIAN NORDIC RESEARCH INSTITUTE GMBH FRAUNHOFERSTRASΞE 18B D-82152 MARTINSRIED GERMANY
NAME AND ADDRESS OF DEPOSITOR
Figure imgf000048_0002
IDENTIFICATION OF THE MICROORGANISM
Identification reference given by the Accession number given by the DEPOSITOR: INTERNATIONAL DEPOSITARY AUTHORITY:
MVA-575 V00120707
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified under I above was accompanied by:
X A scientific description
A proposed taxonomic designation
(Mark with a cross where applicable)
III. RECEIPT AND ACCEPTANCE
This International Depository Authority accepts the microorganism identified under I above, which was received by it on 7™ December 2000 (date of the original deposit)1
IV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under I above was received by this International
Depository Authority on (date of the original deposit) and
A request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)
IV. INTERNATIONAL DEPOSITORY AUTHORITY
Name: Dr P J Packer Signature (s) of person (s) having the power to represent the International Depository Authority or of -authorized officials (s) :
Address: ECACC CAMR .-• I Porton Down Date: ; ' • '• - >ϊ . .- t Salisbury SP4 OJG
Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired
Form BP/4 (sole page) 1991 APPENDIX 3
Page 24
BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
VIABILITY STATEMENT Issued pursant to Rule 10.2 by the
Figure imgf000049_0001
INTERNATIONAL DEPOSITARY AUTHORITY identified on the following page GERMANY
NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY OF STATEMENT
IS ISSUED
DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: BAVARIAN NORDIC RESEARCH INSTITUTE GMBH Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY:
00120707
Address: FRAUNHOFERSTRASSE 18B D-82152 MARTINSRIED Date of the deposit or of the transfer: GERMANY 7™ December 2000
II. VIABILITY STATEMENT
The viability of the microorganism identified under II above was tested on 2. On that date, the said microorganism was viable no longer viable
Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most relevant date (date of the new deposit or date of the transfer) .
In the cases referred to in Rule 10.2 (a) (ii) and (iii) , refer to the most recent viability test.
Mark with a cross the applicable box.
Form BP/4 (first page) Appendix 3 Page 25
Figure imgf000050_0001
Fill in if the in ormation has been requested and if the results of the test were negative .
Form BP/9 (second and last page) Certificate of Analysis
Product Description MVA-575 Accession Number 00120707
Test Description: Determination of TCID50 of cytopathic Virus titration. (SOP ECACC/055) Cell
Acceptance Criterion/Specification/Criteria: Negative controls should show no sign of Cytopathic effects. The Test Sample is serially diluted into in 4 wells of indicator ceil lines for each dilution. Cytopathic effects indicate that virus is present. Virus titre is calculated using the below equation where x is the value obtained from a standard TCID50 Table as a result of the distribution of the wells displaying less than 4 positive wells per dilution, and y is the value of the highest dilution where all 4 wells are positive:
Figure imgf000051_0001
Date: 19/01/01
Result: Indicator Cell Line: BHK 21 CLONE 13
Negative Control: NO CPE
Test Sample: CPE
Distribution of less that 4 positive wells: 4, 4, 0
X: 0.50
Y: • 10-5
TCID50 = 1 x l01 + 0-50 lO-5
Figure imgf000051_0002
Overall Result: Virus Present
Test Description: The Detection of Mycopiasma by Isolation on Mycopiasma Pig Serum Agar and in Mycopiasma Horse Serum Broth. SOP QC/MYCO/01/02
Acceptance Criterion/Specification: All positive controls ( pneumoniae & M. orale) must show evidence of mycopiasma by typical colony formation on agar plates. Broths are subcultured onto Mycopiasma Pig Serum Agar where evidence of mycopiasma by typical colony formation is evaluated. All negative control agar plates must show no evidence of microbial growth.
The criteria for a positive test result is evidence of mycopiasma by typical colony formation on agar. A negative result will show no such evidence. Test Number: 21702 Date: 12/02/01
Result: Positive Control: Positive
Negative Control: Negative
Test Result: Negative
Overall Result: PASS
Figure imgf000051_0003
Page 1 of 1 Certificate of Analysis
Product Description MVA-575 Accession Number 00120707
Test Description: Detection of Mycopiasma using a Vero indicator cell line and Hoechst 33258 fluorescent detection system. SOP QC/MYCO/07/05
Acceptance Criterion/Specification: The Vero cells in the negative control are clearly seen as fluorescing nuclei with no cytoplasmic fluorescence. Positive control ( . orale) must show evidence of mycopiasma as fluorescing nuclei plus extra nuclear fluorescence of mycopiasma DNA. Positive test results appear as extra nuclear fluorescence of mycopiasma DNA. Negative results show no cytoplasmic fluorescence.
Test Number: 21702
Date: 12/02/01
Result:
Positive Control: Positive Negative Control: Negative Test Result: Negative Overall Result: PASS
Test Description: Detection of bacteria and fungi by isolation on Tryptone Soya Broth (TSB) and in Fluid Thioglycollate Medium (FTGM). SOP QC/BF/01/02
Acceptance Criterion/Specification: All positive controls (Bacillis subtilus, Clostridium sporogenes and Candida albicans) show evidence of microbial growth (turbidity) and the negative controls show no evidence of microbial growth (clear).
The criteria for a positive test is turbidity in any of the test broths. All broths should be clear for negative test result.
Test Number: 21702
Date: 12/02/01
Result:
Positive Control: Positive
Negative Control: Negative
Test Result: Negative
Overall Result- PASS
Authorised
Figure imgf000052_0001
Head of Quality...r./ .( .J. Date
Page 2 of 4 Applicant's or agent's file International application No. reference number BN 46 PCT
INDICATIONS RELATING TO ADEPOSITED MICROORGANISM
(PCT Rule 13Zώ)
Figure imgf000053_0001
For International Bureau use only
I I This sheet wasreceivedby the International Bureau on:
Authorized officer
Figure imgf000053_0002
APPENDIX 3
Page 1
BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE O INTERNATIONAL FORM
PROF DR ANTON MAYR WEILHEIMER STR. 1 D-82319 STARNBERG GERMANY
NAME AND ADDRESS OF DEPOSITOR
Figure imgf000054_0001
Figure imgf000054_0002
Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired
Form BP/4 (sole page) 1991 APEENDIX 3
Page 24
BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE .
INTERNATIONAL FORM
VIABILITY STATEMENT Issued pursant to Rule 10.2 by the
Figure imgf000055_0001
INTERNATIONAL DEPOSITARY AUTHORITY D-82319 STARNBERG identified on the following page GERMANY
NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY OF STATEMENT
IS ISSUED
DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name : PROF DR ANTON MAYR Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY:
01021411
Address : WEILHEIMER STR. 1 D-82319 STARNBERG Date of the deposit or of the transfer: GERMANY 14 February 2001
II. VIABILITY STATEMENT
The viability of the microorganism identified under II above was tested on 2. On that date, the said microorganism was viable no longer viable
Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most relevant date (date of the hew deposit or date of the transfer) .
In the cases referred to in Rule 10.2 (a) (ii) and (iii) , refer to the most recent viability test.
Mark with a cross the applicable box.
Form BP/4 (first page) Appendix 3 Page 25
Figure imgf000056_0001
Fill in if the information has been requested and if the results of the test were negative.
Form BP/9 (second and last page) Applicant's or agent's file International applicationNo. referencenumber BN 46 PCT
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule I3bis)
Figure imgf000057_0001
APPENDIX 3
Page 14
BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
TO INTERNATIONAL FORM
PROF. DR. DR. H.C ULT. ANTON MAYR WEILHEIMER STR. 1 D-82319 STARNBERG GERMANY
NAME AND ADDRESS OF DEPOSITOR
Figure imgf000058_0001
IDENTIFICATION OF THE MICROORGANISM
Identification reference given by the Accession number given by the DEPOSITOR: INTERNATIONAL DEPOSITARY -AUTHORITY:
VERO-MVA V9910143l
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified under I above was accompanied by:
X A scientific description
A proposed taxonomic designation
(Mark with a cross where applicable)
III. RECEIPT AND ACCEPTANCE
This International Depository Authority accepts the microorganism identified under I above, which was received by it on 14™ October 1999 (date of the original deposit)1
IV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under I above was received by this International
Depository Authority on (date of the original deposit) and
A request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)
IV. INTERNATIONAL DEPOSITORY AUTHORITY
Name: Dr P J Packer Signature (s) of persόn(s) having the power to represent the International Depository Authority or of authorised officials (s) :
Address: ECACC CAMR
Porton Down Date: Salisbury SP4 OJG -?ιχ D' ϊ&λ
Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired
Form BP/4 (sole page) 1991 APPENDIX 3
Page 24'
BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
VIABILITY STATEMENT
Figure imgf000059_0001
Issued pursant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY D-82319 STARNBERG GERMANY identified on the following page
NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY OF STATEMENT
IS ISSUED
Figure imgf000059_0002
I. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: PROF. DR. DR.H.C. MULT. ANTON MAYR Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY:
V99101431
Address: WEILHEIMER STR. 1 D-82319 STARNBERG Date of the deposit or of the transfer: GERMANY 14™ October 1999
II. VIABILITY STATEMENT
The viability of the microorganism identified under II above was tested
On that date, the said microorganism was
X viable
no longer viable
Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most relevant date (date of the new deposit or date of the transfer) .
In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent viability test.
Mark with a cross the applicable box.
Form BP/4 (first page) Appendix 3 Page 25
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED
VERO-MVA - 99101431
THE VIRUS WAS GROWN ON VERO CELLS ACCORDING TO THE DEPOSITORS INSTRUCTIONS. THE VIRUS WAS VIABLE PRODUCING CYTOPATHIC EFFECT AFTER 48 HOURS. A LITRE OF 6 X 106 PLAQUE FORMING UNITS/ML WAS OBTAINED.
V . INTERNATIONAL DEPOSITARY AUTHORITY
Name : Dr P J Packer
ECACC CAMR Signature (s) of person(s) having the power to represent the International Depositary
Address : Porton Down Authority or of authorized official (s ) :
Salisbury Wiltshire SP4 OJG Date: gfeto-i ύ>2v-
Fill in if the information has been requested and if the results of the test were negative.
Form BP/9 (second and last page)
Figure imgf000061_0001
INDICATIONS RELATING TO ADEPOSITED MICROORGANISM
(PCT Rule Ubis)
Figure imgf000061_0002
Form BP/4 (first page)
Appendix 3 Page 25
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED
V00083008 - MVA-BN
VIABILITY OF MVA-BN MAS TESTED BY GROWING THE VIRUS ON BHK CELLS AND CALCULATING THE TCD50.
V. INTERNATIONAL DEPOSITARY AUTHORITY
Name : Dr P J Packer
ECACC CAMR Signature (s) of person (s) having the power to represent the International Depositary
Address : Porton Down Authority or of authorized official (s) :
Salisbury- Wiltshire SP4 OJG Date : ϊ h v V •&3?Ϋ« /
4 Fill in if the information has been requested and if the results of the test were negative .
APPENDIX 3
Page 24
BUDAPEST TREATY ON THE INTERNATIONAL .
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
VIABILITY STATEMENT Issued pursant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified on the following page D-82152 MARTINSRIED GERMANY
NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY OF STATEMENT
IS ISSUED
I. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: BAVARIAN NORDIC RESEARCH Accession number given by the INSTITUTE GMBH INTERNATIONAL DEPOSITORY AUTHORITY:
V00083008
Address: FRAUNHOFERSTRASSE 18B D-82152 MARTINSRIED Date of the deposit or of the transfer: GERMANY 30™ August 2000
II. VIABILITY STATEMENT
The viability of the microorganism identified under II above was tested
On that date, the said microorganism was viable
no longer viable
Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most relevant date (date of the new deposit or date of the transfer) .
In the cases referred to in Rule.10.2 (a) (ii) and (iii), refer to the most recent viability test.
Mark with a cross the applicable box. APPENDIX 3
Page 14
BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
TO INTERNATIONAL FORM
Figure imgf000064_0001
BAVARIAN NORDIC RESEARCH INSTITUTE GMBH FRAUNHOFERSTRASSE 18B D-82152 MARTINSRIED GERMANY
NAME AND ADDRESS OF DEPOSITOR
Figure imgf000064_0002
I . IDENTIFICATION OF THE MICROORGANISM
Identification reference given by the Accession number given by the DEPOSITOR: INTERNATIONAL DEPOSITARY• AUTHORITY :
MVA-BN V00083008
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified under I above was accompanied by:
~ ζ A scientific description
A proposed taxonomic designation
(Mark with a cross where applicable)
III. RECEIPT AND ACCEPTANCE
This International Depository Authority accepts the microorganism identified under I above, which was received by it on 30τli August 2000 (date of the original deposit)1
IV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under I above was received by this International
Depository Authority on (date of the original deposit) and
A request to convert the original deposit to a deposit under the Budapest Treaty was received by it on ' (date of receipt of request for conversion)
IV. INTERNATIONAL DEPOSITORY AUTHORITY
Name: Dr P J Packer Signature (s) of person(s) having the power to represent the International Depository Authority or of authorized officials (s) :
Address : ECACC CAMR
Porton Down Date: Salisbury SP4 OJG α ls [h/il/a
Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired
Form BP/4 (sole page) 1991 Certificate of Analysis
Product Description MVA-BN Accession Number 00083008
Test Description: The Detection of Mycopiasma by Isolation on Mycopiasma Pig Serum Agar and in Mycopiasma Horse Serum Broth. SOP QC/MYCO/01/02
Acceptance Criterion/Specification: All positive controls (M. pneumoni e & M. orate) must show evidence of mycopiasma by typical colony formaτion on agar plates. Broths are subculture onto Mycopiasma Pig Serum Agar where evidence of mycopiasma by typical colony formation is evaluated. All negative control agar plates must show no evidence of microbial growth.
The criteria for a positive test result is evidence of mycopiasma by typical colony formation on agar. A negative result will show no such evidence.
Test Number: 21487
Dates 27/11/00
Result;
Positive Control: Positive Negative Control: Negative
Test Result: Negative Overall Result: PASS
Test Description: Detection of Mycopiasma using a Vero indicator cell line and Hoechst 332S8 fluorescent detection systcm. SOP QCVMYCO/07/05
Acceptance Criterion/Specification: The Vero cells in the negative control are clearly seen as fluorescing nuclei with no cytoplasmic fluorescence. Positive control (M. arale) must show evidence of mycopiasma as fluorescing nuclei plus extra nuclear fluorescence of mycopiasma DNA. Positive test results appear as extra nuclear fluorescence of mycopiasma DNA. Negative results show no cytoplasmic fluorescence.
Test Number: 21487
Date: 27/11/00
Result:
Positive Control: Positive
Negative Control: Negative
Test Result: Negative
Overall Result: PASS
Authorised by. WWft/. T. ECACC, Head of Quality _ .&/.&>_. Daie
Page l of 2 Certificate of Analysis
Produc Description MVA-BN Accession Number 00083008
Test Description; Detection of bacteria and fungi by isolation on Trvptone Soya Broth (TSB) and in Fluid Thioglycollate Medium (FTGM). SOP QC BF/01/02
Acceptance Criterion/Specification: All positive controls {Bacillis subrilus, Closrridium sporogenes and Candida albicans) show evidence of microbial growth (turbidity) and the negative controls show no evidence of microbial growth (clear).
The criteria for a positive test is turbidity in any o the test broths. AH broths should be clear for negative test result.
Test Number: 21487
Date: 27/11/00
Result:
Positive Control: Positive Negative Control: Negative Test Result: Negative Overall Result: PASS
Test Description; Determination ofTCIDso of cytopathic Virus titration. (SOP ECACC/055) Cell
Acceptance Criteriσπ/Specification/Criteria: Negative controls should show no sign of Cytopathic effects. The Test Sample is serially diluted into in 4 wells of indicator cell lines for each dilution. Cytopathic effects indicate that virus is present. Virus titre is calculated using the below equation where x is the value obtained from a standard TCIDS0 Table as a result ofthe distribution ofthe wells displaying less than 4 positive wells per dilution, and y is the value of the highest dilution where all 4 wells are positive: .
TCIDJO = I x lO' y
Date: 01/12/00
Result:
Indicator Cell Line: BHK21 (Clone 13)
Negative Control: NO CPE
Test Sample: CPE
Distribution of less that 4 positive wells: 4, 4, 4, 3, 0
X: 1.25
Y: 10-3
TCIDSQ = 1 lO' + 01.25 10-7
= = 1 in0«*
Overall Result: Virus Present
' *** End ot Certificate*""1'
Authorised bbyy. ttϊs. aJ Ml.?!-.. ECACC, Head of Quality hL <3r... τ> tc
Page 2 of 2

Claims

C L A I M S
1. A recombinant poxvirus comprising at least two homologous foreign genes, wherein each of said genes is inserted into a different insertion site of the viral genome .
2. The recombinant poxvirus according to claim 1, wherein the genes have a homology of at least 50%.
3. A recombinant poxvirus comprising at least two homologous foreign genes, said genes having a homology of at least 60%.
4. The recombinant poxvirus according to claim 2 or 3 , wherein the genes have a homology of 65-75%.
5. The recombinant poxvirus according to claims 1 to 4, wherein the genes are derived from a flavivirus .
6. The recombinant poxvirus according to claim 5, wherein the flavivirus is a Dengue virus.
7. The recombinant poxvirus according to claim 5 or 6, wherein the genes are at least two homologous genes derived from at least two different serotypes of the virus.
8. The recombinant poxvirus according to claims 5 to 7 , wherein the genes are at least two PrM genes .
9. The recombinant poxvirus according to claims 5 to 8 , wherein the genes are 4 PrM genes .
10. The recombinant poxvirus according to claims 1 to 9 , wherein the poxvirus is a Vaccinia virus.
11. The recombinant poxvirus according to claim 10, wherein the Vaccinia virus is a Modified Vaccinia Ankara (MVA) virus .
12. The recombinant poxvirus according claim 11, wherein the MVA is MVA-BN deposited at the European Collection of Animal Cell Cultures (ECACC) under number V00083008.
13. The recombinant poxvirus according to claims 1 to 12, wherein the poxvirus is replication deficient or replication incompetent in mammalian cells, including human cells .
14. The recombinant poxvirus according to claims 1 to 13, wherein the genes are inserted into a naturally occurring deletion site and/or into an intergenic region of the poxviral genome.
15. The recombinant poxvirus according claims 1 to 14 as medicament or vaccine.
16. A vaccine comprising the recombinant poxvirus according to any of the claims 1 to 14.
17. A pharmaceutical composition comprising the recombinant poxvirus according to any of the claims 1 to 14 and a pharmaceutically acceptable carrier, diluent, adjuvant and/or additive.
18. The recombinant poxvirus according to any of the claims 1 to 14, the vaccine according to claim 16 or the composition according to claim 17 for affecting, preferably inducing, an immune response of a living animal, including a human.
19. Use of the recombinant poxvirus according to any of the claims 1 to 14 for the preparation of a medicament.
20. A method for affecting, preferably inducing, an immune response in a living animal, including a human, comprising administering a therapeutically effective amount of the recombinant poxvirus according to any of the claims 1 to 14, the vaccine according to claim 16 or the composition according to claim 17 to the animal or human to be treated.
21. A cell comprising the recombinant poxvirus according to claims 1 to 14.
22. A method for producing a recombinant poxvirus according to claims 1 to 14 comprising the steps of
infecting a cell with a poxvirus;
transfecting the infected cell with a first vector construct comprising a gene being heterologous to the poxviral genome, and a genomic poxvirus sequence capable of directing the integration of the heterologous gene into an insertion site of the poxviral genome;
identifying, isolating and, optionally, purifying the generated recombinant poxvirus ; - repeating the above steps by using the recombinant poxvirus obtained from previous steps for infecting the cell and an additional vector construct comprising a further gene being heterologous to the poxviral genome and homologous to the gene of the first vector construct.
23. A kit comprising
two or more vector constructs, each construct comprising a gene under transcriptional control of a poxviral expression control element, wherein the genes included in the different vectors are homologous genes, and wherein each gene is flanked by a poxviral DNA sequence capable of directing the integration of the gene into a poxviral genome, and means for identifying and/or selecting recombinant poxviruses, which have incorporated said homologous genes into their genome.
24. The kit according to claim 23, wherein each homologous gene is flanked by a poxviral DNA sequence capable of directing the integration of said homologous gene of each vector construct into a different insertion site of the poxviral genome .
25. A DNA sequence derived from or homologous to the recombinant poxviral genome of the recombinant poxvirus according to claims 1 to 14, wherein said DNA sequence comprises at least two homologous genes and at least part of the sequences of the poxviral genome.
26. A method for detecting cells infected with the recombinant poxvirus according to claims 1 to 14, said method comprising administering the DNA sequence according to claim 25 to said cells.
27. A method for identifying the recombinant poxvirus according to claims 1 to 14, said method comprising administering the DNA sequence according to claim 25 to said virus.
PCT/EP2003/005047 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome WO2003097846A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
JP2004506501A JP4693092B2 (en) 2002-05-16 2003-05-14 Recombinant poxvirus that expresses a homologous gene inserted into the poxvirus genome
DK03735384T DK1506301T3 (en) 2002-05-16 2003-05-14 RECOMBINANT POXVIRUS THAT EXPRESSES HOMOLOGICAL GENES INTO THE POXVIRUS GENE
NZ536502A NZ536502A (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome for inducing an immune response in a mammal
CN038111063A CN1653183B (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
BR0310051A BR0310051A (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
CA2481799A CA2481799C (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
MXPA04011194A MXPA04011194A (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome.
KR1020047018293A KR101005630B1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
EA200401506A EA012160B1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome and use thereof
US10/510,189 US7338662B2 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the foxviral genome
IL16417703A IL164177A0 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
KR1020107021891A KR101138067B1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
EP20030735384 EP1506301B1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
AU2003236646A AU2003236646B2 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
NO20044940A NO334273B1 (en) 2002-05-16 2004-11-12 Recombinant poxvirus, and its use, vaccine, pharmaceutical composition, cell, method for generating a recombinant poxvirus, kit, DNA sequence and use thereof
HK05108644A HK1076642A1 (en) 2002-05-16 2005-09-29 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US11/985,510 US9109233B2 (en) 2002-05-16 2007-11-15 Recombinant poxvirus expressing homologous genes inserted
IL193087A IL193087A (en) 2002-05-16 2008-07-28 Dna from a recombinant poxvirus expressing homologous genes inserted into the poxviral genome
IL19308808A IL193088A (en) 2002-05-16 2008-07-28 Recombinant modified vaccinia ankara (mva) virus expressing homologous genes inserted into the mva genome
US12/339,743 US20100173388A1 (en) 2002-05-16 2008-12-19 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US12/894,589 US20110053260A1 (en) 2002-05-16 2010-09-30 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US12/894,550 US20110053259A1 (en) 2002-05-16 2010-09-30 Recombinant poxvirus expressing homologous genes inserted into the poxvirus genome
NO20111324A NO20111324A1 (en) 2002-05-16 2011-09-29 Recombinant MVA virus
US13/371,580 US20120178157A1 (en) 2002-05-16 2012-02-13 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200200752 2002-05-16
DKPA200200753 2002-05-16
DKPA200200752 2002-05-16
DKPA200200753 2002-05-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10510189 A-371-Of-International 2003-05-14
US11/985,510 Continuation US9109233B2 (en) 2002-05-16 2007-11-15 Recombinant poxvirus expressing homologous genes inserted

Publications (1)

Publication Number Publication Date
WO2003097846A1 true WO2003097846A1 (en) 2003-11-27

Family

ID=29551228

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2003/005047 WO2003097846A1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
PCT/EP2003/005045 WO2003097845A1 (en) 2002-05-16 2003-05-14 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005045 WO2003097845A1 (en) 2002-05-16 2003-05-14 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Country Status (23)

Country Link
US (14) US7338662B2 (en)
EP (3) EP1506301B1 (en)
JP (4) JP4895505B2 (en)
KR (4) KR20120002627A (en)
CN (6) CN101831411A (en)
AT (1) ATE315660T1 (en)
AU (4) AU2003242540A1 (en)
BR (2) BRPI0311178B8 (en)
CA (3) CA2812019A1 (en)
DE (1) DE60303218T2 (en)
DK (2) DK1506301T3 (en)
EA (3) EA020230B1 (en)
ES (1) ES2256776T3 (en)
HK (2) HK1076642A1 (en)
IL (4) IL164172A0 (en)
MX (2) MXPA04011194A (en)
NO (3) NO334273B1 (en)
NZ (2) NZ536502A (en)
PL (2) PL218318B1 (en)
PT (1) PT1407033E (en)
SI (1) SI1407033T1 (en)
UA (1) UA82479C2 (en)
WO (2) WO2003097846A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142479A3 (en) * 2006-08-25 2009-06-25 Us Gov Health & Human Serv Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
WO2010057650A1 (en) * 2008-11-21 2010-05-27 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
US7951576B2 (en) * 2004-11-05 2011-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for preparing cells and viruses
US20120039937A1 (en) * 2006-11-09 2012-02-16 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
WO2012048817A2 (en) 2010-10-15 2012-04-19 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara influenza vaccine
WO2012040474A3 (en) * 2010-09-23 2012-07-19 Baxter International Inc. Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
US8241638B2 (en) * 2006-11-09 2012-08-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
US8795681B2 (en) * 2007-05-30 2014-08-05 Boehringer Ingelheim Vetmedica, Inc. Raccoon poxvirus expressing rabies glycoproteins
WO2016202828A1 (en) * 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
WO2017060650A1 (en) 2015-10-08 2017-04-13 Jean-Marc Limacher Anti-tumoral composition

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (en) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
CZ295808B6 (en) * 2000-11-23 2005-11-16 Bavarian Nordic A/S Modified vaccinia Ankara virus variant
MXPA04010353A (en) * 2002-04-19 2005-03-07 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates.
CN101831411A (en) * 2002-05-16 2010-09-15 巴法里安诺迪克有限公司 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EA009008B1 (en) * 2002-09-05 2007-10-26 Бавариан Нордик А/С Method for amplification of poxviruses
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
PT1855720T (en) * 2005-02-23 2016-12-14 Bavarian Nordic As Use of a modified proxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
EP2027271A4 (en) * 2006-05-19 2010-06-09 Glycofi Inc Recombinant vectors
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
EP2390340A3 (en) * 2007-01-30 2012-02-22 Transgene SA vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
CN101688223B (en) * 2007-05-15 2013-07-31 特兰斯吉恩股份有限公司 Vectors for multiple gene expression
WO2008150404A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens
WO2009052328A1 (en) * 2007-10-18 2009-04-23 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
KR100894430B1 (en) * 2008-11-11 2009-04-22 시스템디엔디(주) Device and method for measuring fluid leakage rate of a valve using ultrasonic, acoustic and temperature detection system
JP2013507107A (en) 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Generation of broad T cell responses in humans to HIV
AU2010306559B2 (en) 2009-10-16 2015-07-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
AU2011230491A1 (en) * 2010-03-26 2012-10-18 Emergent Product Development Gaithersburg Inc. Ectodomains of influenza Matrix 2 protein, expression system, and uses thereof
CA2802430C (en) 2010-07-20 2021-07-20 Bavarian Nordic A/S Method for harvesting poxvirus
CN114262690A (en) 2011-04-15 2022-04-01 吉恩勒克斯公司 Clonal strains of attenuated vaccinia virus and methods of use thereof
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP3530283A1 (en) 2012-06-05 2019-08-28 The Australian National University Vaccination with interleukin-4 antagonists
US9480738B2 (en) 2012-08-01 2016-11-01 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2014062778A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
KR102212253B1 (en) * 2013-03-15 2021-02-04 세멘티스 리미티드 Immune modulation
DE102013004595A1 (en) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV vaccines
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101645642B1 (en) 2014-10-16 2016-08-11 대한민국 Kvac recombinant vaccinia virus derived from kvac strain
KR101623498B1 (en) 2014-10-16 2016-05-24 대한민국 Kvacattenuated vaccinia virus kvac strain
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
WO2016168862A1 (en) 2015-04-17 2016-10-20 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
KR20160140075A (en) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 Promoter derived from the poxviridae and vector including the same
CN106591361A (en) * 2015-10-20 2017-04-26 钱文斌 Recombinant pox oncolytic virus, and construction method and application thereof
AU2017206102C1 (en) 2016-01-08 2022-02-10 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
ES2921605T3 (en) * 2016-01-29 2022-08-30 Bavarian Nordic As Equine encephalitis virus vaccine based on recombinant Ankara modified vaccinia virus (AMV)
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
KR20180133395A (en) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 Replicable attenuated vaccinia virus with or without the expression of human FLT3L or GM-CSF and for which the thymidine kinase has been deleted for cancer immunotherapy
EP3419662A4 (en) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
WO2018032057A1 (en) * 2016-08-19 2018-02-22 Sementis Limited Viral vaccines
WO2018064516A1 (en) * 2016-09-30 2018-04-05 Monsanto Technology Llc Method for selecting target sites for site-specific genome modification in plants
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
BR112019026126A2 (en) * 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. poxvirus vectors encoding HIV antigens and methods of using them
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
JP2021523712A (en) 2018-05-11 2021-09-09 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Genetically modified recombinant Vaccinia ankara (RMVA) vaccine with improved stability and its preparation method
WO2019216929A1 (en) * 2018-05-11 2019-11-14 City Of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
CN111979204B (en) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 Oncolytic vaccinia virus carrying sponge lectin gene, construction method and application
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5494807A (en) * 1991-03-07 1996-02-27 Virogenetics Corporation NYVAC vaccinia virus recombinants comprising heterologous inserts
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
WO1998013500A2 (en) 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US5891442A (en) 1991-07-26 1999-04-06 Virogenetics Corporation Infectious bursal disease virus recombination poxvirus vaccine
US6217882B1 (en) 1989-04-21 2001-04-17 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
WO2002018585A2 (en) * 2000-08-29 2002-03-07 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795956B2 (en) * 1986-09-22 1995-10-18 京都大学長 Expression control region derived from poxvirus
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
BE1004877A3 (en) * 1991-05-27 1993-02-16 Solvay RECOMBINANT AVIPOX VIRUS, CULTURE OF CELLS INFECTED WITH THIS VIRUS AND POULTRY VACCINES DERIVED FROM THIS VIRUS.
FR2679249B1 (en) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique YEAST STRAINS WITH STABLE INTEGRATION OF HETEROLOGOUS GENES.
ATE253123T1 (en) 1991-08-26 2003-11-15 Baxter Healthcare Sa A RECOMBINANT BIRD POX VIRUS CONTAINING AN INTACT FPV-TK GENE
ATE181108T1 (en) * 1991-08-26 1999-06-15 Immuno Ag DIRECT MOLECULAR CLONING OF A MODIFIED GENOME OF A CHORDOPOX VIRUS
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
DE19629828A1 (en) * 1996-07-24 1998-01-29 Bayer Ag Carbanilides
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
US6682742B1 (en) * 1999-05-28 2004-01-27 Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
CN1291012C (en) * 2000-03-14 2006-12-20 巴法里安诺迪克有限公司 Altered strain of modified vaccinia virus ankara (MVA)
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
CN101831411A (en) * 2002-05-16 2010-09-15 巴法里安诺迪克有限公司 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR20050083839A (en) * 2002-11-25 2005-08-26 버베리안 노딕 에이/에스 Recombinant poxvirus comprising at least two cowpox ati promoters

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US6217882B1 (en) 1989-04-21 2001-04-17 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494807A (en) * 1991-03-07 1996-02-27 Virogenetics Corporation NYVAC vaccinia virus recombinants comprising heterologous inserts
US5891442A (en) 1991-07-26 1999-04-06 Virogenetics Corporation Infectious bursal disease virus recombination poxvirus vaccine
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
WO1998013500A2 (en) 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO2002018585A2 (en) * 2000-08-29 2002-03-07 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1998, JOHN WILEY AND SON INC., article "Chapter 16,"
AJ DAVISON AND RM ELLIOTT: "Molecular Virology: A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS
BRAY ET AL., VIROLOGY, 1989, pages 2853 - 2856
BRIAN WJ MAHY AND HILLAR O KANGRO: "Virology Methods Manual", 1996, ACADEMIC PRESS
DEUBLE ET AL., J. VIROL, vol. 65, 1988, pages 2853
FIELDS B.N.,: "Fields Virology", LIPPINCOTT-RAVEN PUBLISHERS, article "Chapter 83 and 84"
FIELDS B.N.,: "Fields Virology, 3rd edition", 1996, LIPPINCOTT-RAVEN PUBLISHERS, article "Chapter 83"
FIELDS B.N.: "Fields Virology, 4th edition", 2001, LIPPINCOTT-RAVEN PUBLISHERS
HOWLEY P M ET AL: "A functional measles virus replication and transcription machinery encoded by the vaccinia virus genome.", JOURNAL OF VIROLOGICAL METHODS. NETHERLANDS APR 1999, vol. 79, no. 1, April 1999 (1999-04-01), pages 65 - 74, XP002257129, ISSN: 0166-0934 *
J. SAMBROOK; E.F. FRITSCH; T. MANIATIS: "Molecular Cloning, A laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
MACKETT; ARCHARD, J GEN VIROL, vol. 45, 1979, pages 683 - 701
MAYR, A. ET AL., INFECTION, vol. 3, 1975, pages 6 - 14
MEYER, H. ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038
MOSS, IMMUNOLOGY, vol. 2, 1990, pages 317 - 327
PERKUS ET AL., SCIENCE, vol. 229, 1985, pages 981 - 984
SMITH ET AL., BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, vol. 2, 1984, pages 383 - 407
SMITH; MOSS, GENE, vol. 25, no. 1, 1983, pages 21 - 28
STICKL, H. ET AL., DTSCH. MED. WSCHR., vol. 99, 1974, pages 2386 - 2392
SUTTER ET AL., VACCINE, vol. 12, 1994, pages 1032
SUTTER, G. ET AL., VACCINE, vol. 12, 1994, pages 1032 - 40

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951576B2 (en) * 2004-11-05 2011-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for preparing cells and viruses
EP2402451A3 (en) * 2006-08-25 2012-04-18 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Method for stabilizing an DNA insert in a recombinant vaccinia vector
US10421978B2 (en) 2006-08-25 2019-09-24 The Usa, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus
US9133478B2 (en) 2006-08-25 2015-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes
WO2008142479A3 (en) * 2006-08-25 2009-06-25 Us Gov Health & Human Serv Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
US20120039937A1 (en) * 2006-11-09 2012-02-16 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
US8241638B2 (en) * 2006-11-09 2012-08-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
US8795681B2 (en) * 2007-05-30 2014-08-05 Boehringer Ingelheim Vetmedica, Inc. Raccoon poxvirus expressing rabies glycoproteins
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
WO2010057650A1 (en) * 2008-11-21 2010-05-27 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
KR20110105780A (en) * 2008-11-21 2011-09-27 버베리안 노딕 에이/에스 Vector comprising multiple homologous nucleotide sequences
AU2009317517B2 (en) * 2008-11-21 2014-12-04 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
US8999637B2 (en) 2008-11-21 2015-04-07 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
EA024749B1 (en) * 2008-11-21 2016-10-31 Бавариан Нордик А/С Expression vector with reduced level of intramolecular recombination comprising homologous or heterologous nucleotide sequences
US9540660B2 (en) 2008-11-21 2017-01-10 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
CN106318978A (en) * 2008-11-21 2017-01-11 巴法里安诺迪克有限公司 Vector comprising multiple homologous nucleotide sequences
KR101702956B1 (en) * 2008-11-21 2017-02-06 버베리안 노딕 에이/에스 Vector comprising multiple homologous nucleotide sequences
WO2012040474A3 (en) * 2010-09-23 2012-07-19 Baxter International Inc. Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
WO2012048817A2 (en) 2010-10-15 2012-04-19 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara influenza vaccine
WO2016202828A1 (en) * 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
US11103570B2 (en) 2015-06-15 2021-08-31 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine
WO2017060650A1 (en) 2015-10-08 2017-04-13 Jean-Marc Limacher Anti-tumoral composition

Also Published As

Publication number Publication date
IL193088A0 (en) 2009-02-11
NO334273B1 (en) 2014-01-27
HK1076836A1 (en) 2006-01-27
CN102719408A (en) 2012-10-10
US20110244574A1 (en) 2011-10-06
ES2256776T3 (en) 2006-07-16
US7338662B2 (en) 2008-03-04
EP2253709A1 (en) 2010-11-24
US8435543B2 (en) 2013-05-07
EP1506301A1 (en) 2005-02-16
AU2003242540A1 (en) 2003-12-02
IL164177A0 (en) 2005-12-18
US20090311746A1 (en) 2009-12-17
AU2009200380A1 (en) 2009-02-19
US20110053260A1 (en) 2011-03-03
US20110053259A1 (en) 2011-03-03
DK1407033T3 (en) 2006-05-22
AU2009200380C1 (en) 2010-03-11
US8309326B2 (en) 2012-11-13
JP4693092B2 (en) 2011-06-01
EA200900180A1 (en) 2009-08-28
US20130243813A1 (en) 2013-09-19
IL193087A (en) 2012-10-31
JP2005525823A (en) 2005-09-02
NZ536501A (en) 2006-08-31
US20120178157A1 (en) 2012-07-12
CN100494388C (en) 2009-06-03
NO20111324A1 (en) 2011-09-29
CN1653184A (en) 2005-08-10
KR101005630B1 (en) 2011-01-05
EP1407033B1 (en) 2006-01-11
CN1653183A (en) 2005-08-10
US20120039936A1 (en) 2012-02-16
KR20100110901A (en) 2010-10-13
CA2481521A1 (en) 2003-11-27
PL372088A1 (en) 2005-07-11
EA012160B1 (en) 2009-08-28
BRPI0311178B8 (en) 2021-05-25
JP5777199B2 (en) 2015-09-09
UA82479C2 (en) 2008-04-25
EP1506301B1 (en) 2014-04-30
EA020230B1 (en) 2014-09-30
CA2481799A1 (en) 2003-11-27
CN102703393A (en) 2012-10-03
KR20040108809A (en) 2004-12-24
JP2005525822A (en) 2005-09-02
NO336489B1 (en) 2015-09-07
US7550147B2 (en) 2009-06-23
DK1506301T3 (en) 2014-07-21
US20100303856A1 (en) 2010-12-02
JP2011004755A (en) 2011-01-13
US8414900B2 (en) 2013-04-09
IL164172A0 (en) 2005-12-18
PL216760B1 (en) 2014-05-30
CA2481521C (en) 2012-04-17
US9109233B2 (en) 2015-08-18
DE60303218D1 (en) 2006-04-06
KR20040108798A (en) 2004-12-24
BR0310051A (en) 2005-02-15
BR0311178A (en) 2005-03-29
MXPA04010713A (en) 2005-03-07
EA200401507A1 (en) 2005-06-30
WO2003097845A1 (en) 2003-11-27
MXPA04011194A (en) 2005-02-14
ATE315660T1 (en) 2006-02-15
CN102199628A (en) 2011-09-28
PL218318B1 (en) 2014-11-28
IL193088A (en) 2015-02-26
KR101041691B1 (en) 2011-06-14
EP1407033A1 (en) 2004-04-14
CA2812019A1 (en) 2003-11-27
JP2010259446A (en) 2010-11-18
KR101138067B1 (en) 2012-04-24
EA007811B1 (en) 2007-02-27
AU2009200380B2 (en) 2009-10-01
AU2003236646A1 (en) 2003-12-02
AU2003236646B2 (en) 2009-01-15
SI1407033T1 (en) 2006-06-30
US20120082696A1 (en) 2012-04-05
US8288125B2 (en) 2012-10-16
US20100173388A1 (en) 2010-07-08
US20110250693A1 (en) 2011-10-13
US8034354B2 (en) 2011-10-11
KR20120002627A (en) 2012-01-06
JP4895505B2 (en) 2012-03-14
NO20045480L (en) 2004-12-16
CN1653183B (en) 2012-07-25
US20120135501A1 (en) 2012-05-31
US20060165727A1 (en) 2006-07-27
EP2253709B1 (en) 2018-04-11
EA200401506A1 (en) 2005-04-28
IL193087A0 (en) 2009-02-11
BRPI0311178B1 (en) 2020-11-17
US20050244428A1 (en) 2005-11-03
HK1076642A1 (en) 2006-01-20
PT1407033E (en) 2006-05-31
US7964374B2 (en) 2011-06-21
NO20044940L (en) 2004-11-12
US8741308B2 (en) 2014-06-03
DE60303218T2 (en) 2006-09-14
PL372093A1 (en) 2005-07-11
AU2008255213B2 (en) 2011-10-06
AU2008255213A1 (en) 2009-01-08
CA2481799C (en) 2014-01-28
CN101831411A (en) 2010-09-15
NZ536502A (en) 2005-10-28

Similar Documents

Publication Publication Date Title
CA2481799C (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US8029800B2 (en) Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 164177

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2955/DELNP/2004

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006165727

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10510189

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2481799

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003735384

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003236646

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 536502

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/011194

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047018293

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004506501

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038111063

Country of ref document: CN

Ref document number: 372088

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501831

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 200401506

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1200401336

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020047018293

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003735384

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 536502

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 536502

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 10510189

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 193087

Country of ref document: IL

Ref document number: 193088

Country of ref document: IL